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Ras and Rho proteins, involve in the pathogenesis of more than half of all forms of cancer, 
undergo posttranslational modification with an isoprenyl lipid catalyzed by protein 
farnesyltransferase (FTase) or protein geranylgeranyltransferase-I (GGTase-I). This 
posttranslational modification is termed as prenylation. The attached lipid is required for 
proper function of the modified protein, either as a mediator of membrane association, a 
determinant for specific protein-protein interactions, or both. Accordingly, inhibitors for 
both of these enzymes have been developed. However, farnesyltransferase inhibitors 
(FTIs) have not performed up to expectation in solid tumors and failed to respond in many 
types of cancer. When FTase is inhibited, the human oncogenic Ras isoform K-RasB is 
geranylgeranylated by protein GGTase-I. GGTase-I is the enzyme that catalyzes 
geranylgeranylation, which in turn is important to the function of the majority of Rho 
GTPases and several other regulatory proteins. Earlier studies have demonstrated that 
many of these proteins contribute to tumor development and metastasis. Thus to effectively 
block Ras processing, the development of selective inhibitors of GGTase-I (GGTIs) is 
required. In addition to their potential to suppress alternate prenylation of K-Ras and hence 
impact on K-Ras-dependent oncogensis, GGTIs have been proposed as potential drugs for 
anti-angiogenic therapy and for inhibiting metastatic progression of cancers (via impact on 
xx 
 
proteins such as RhoA/C), inflammatory disorders and those of vascular system, and for 
hepatitis C.  
In this study, a series of pyrazole-based GGTIs, structural analogues of GGTI-DU40, 2-16 
have been synthesized and biologically evaluated for their GGTas-1 and 
farnesyltransferase (FTase) inhibition. The screening results revealed that 2 (IC50 = 2.4 
µM) and 5 (IC50 = 3.1 µM) are potent inhibitors of GGTase-I, possessing higher inhibitory 
activity compared to the control compound 1 (GGTI-DU40, IC50 = 3.3 µM). The anti-
proliferative efficacies against MDA-MB-231 cells line of target compounds demonstrated 
a significantly higher activity of 2 (IC50 = 7.6 µM) compared to 1 (IC50 = 23.0 µM). The 
efficiency of the target compounds was further validated by western blot analysis in MDA-
MB-231 cell line, which revealed very high inhibitory cellular activity of 2 and 5, 
demonstrating their capacity to inhibit prenylation of endogenous proteins. Molecular 
docking studies of 2 with the crystal structure of GGTase-I complexed with a 
geranylgeranyl pyrophosphate (GGPP) Analog and a CaaX (C = cysteine, aa = aliphatic 
amino acids, and X = any amino acid) portion of the KKKSKTKCVIL peptide substrate 
revealed several H-bonding interactions and π-π contacts between 2 and the binding pocket 


























 محمد منشاء    :االسم الكامل
  
 
  ، وهو هدف لألدوية I-GGTaseدياريل بيرازولس كمثبطات -1،3تصميم وتوليف وتقييم       :عنوان الرسالة
 المضادة للسرطان
 
 كيمياء             التخصص:
 
   2017مايو  :تاريخ الدرجة العلمية
 ا
" بالتسبب بأكثر من نصف جميع أشكال السرطان، وتخضع لتعديالت Ras and Rhoتدخل البروتينات راس ورو "
 (farnesyltransferase "(FTase" فارنيسيلترانزفيراسما بعد متعدية مع لبيد أيزوبرين المحفزة من قبل البروتين 
ما بعد . ويعمل تعديل I-geranylgeranyltransferase "I)-(GGTase" 1-جيرانيلجيرانييلترانزفيراسأو البروتين 
". وتكون الدهون المرفقة مطلوبة من prenylationمتعدية إلى تحويل البروتينات إلى بروتينات كاره للماء وتدعى "
أو محددا لتفاعالت بروتينبروتين معينة  أو كليهما.  غشاء الجمعيةإما كوسيط أجل وظيفة مناسبة للبروتين المعدل، 
( FTIs) فارنيسيلترانزفيراسومع ذلك فإن مثبطات البروتين  االنزيمات.وبناء على ذلك، ُطورت مثبطات لكل من هذه 
 "FTase" عندما يثبط األنزيم فيتس في االستجابة في العديد من أنواع السرطان.لم تنفذ بعد ليتوقع أورام صلبة وقشل 
ع لتعديالت يجعله يخض "Ras" الشكل األيزو للبروتين راس " RasB -Kفإن المورثة الرومية البشرية للبروتين "
" هو األنزيم المحفز   I-GGTase" 1-". جي جي تاسI-GGTase" 1-كاره للماء بواسطة البروتين جي جي تاس 
 " و جي تي باس "  Rhoللتفاعالت التي تجعل البروتين كاره للماء، والتي بدورها مهمة لتوظيف البروتينات رو "
GTPases األخرى. " و العديد من البروتينات التنظيمية 
 الورم الخبيث. وهكذا لمنع فعالية وقد أظهرت الدراسات السابقة أن العديد من هذه البروتينات تسهم في تطور الورم و
".   I-GGTase" 1-" يتطلب ذلك تطوير انتقائي للمثبطات من نوع جي جي تاس  Rasمالجة البروتين راس "
" وبالتالي التأثير على  Ras -Kراس "-بإلضافة إلى امكانية تثبيط التفاعالت الكاره للماء لبديلة الناتجة من البروتين ك
"" كأدوية لعالج المضادة لألوعية ولمنع  1-" المعتمدة على تكوين الورم. أُقترح جي جي تاس Ras -Kراس "-ك
 .Cوأمراض الجهاز الوعائي والتهاب الكبد  واضطرابات التهاباتتطور الورم إلى  سرطان 
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" وكذلك  GGTIs" ذات أساس بروتيني من جي جي تاس " pyrazoleفي هذه الدراسة، ُصنعت سلسلة من بيرازول "
وقُيمت بيولوجيا مقارنة مع المثبطات جي  DU40-GGTI " 2-16" 40دي يو –النظائر البنيوية لـ جي جي تي اي 
50IC ) 2". كشفت نتائج الفحص المركب farnesyltransferase" رنيسيلترانزفيراسفا" وGGTas-1" 1-جي تاس
= 2.4 µM 3.1 =) 5( والمركب µM 50IC1-( أنها مثبطات أقوى من جي جي تاس "I-GGTase  وتمتلك نشاطا "
 (. واظهرت نتائج تاثير مضادات التكاثر على الخاليا µM 50DU40, IC-GGTI 3.3 =) 1أعلى مقارنة مع المركب 
 231-MB-MDA  7.6 =) 2فعالية عالية نسبيا للمركب µM 50IC 23.0 =) 1( مقارنة بالمركب µM 50IC  .) 
الذي كشف  MB-MDA-231 تم التحقق من كفاءة المركبات المستهدفة من خالل تحليل لطخة غربية في خط الخلية
 ، مما يدل على مقدرتهما في تثبيط تحول البروتينات الذاتية إلى كاره للماء.5و 2عن فعالية تثبيط عالية جدا للمركبين 
 جيرانيلجيرانيل بيروفوسفاتو  1-مع البنية البلورية لجي جي تاس 2كشفت الدراسة الجزيئية لمعقد إرتباط المركب 
"geranylgeranyl pyrophosphate ( "GGPP( وأيضا الساكس )CaaX س= سيستين وأ= ألفا أمينو اسيد و ( )
( العديد من تفاعالت الرابطة هدروجين مع و KKKSKTKCVILأكس= أَي حمض أميني( جزء من ركيزة الببتيد )
دراسة  يلزمه 2. لذك النشاط العالي في المختبر الحيوي لـ 1-و جيب من جي جي تاس 2(  بين π-πباي )–الرابطة باي 









 2-16الهياكل الكيميائية من المركبات المستهدفة 
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1 CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
Protein prenylation is one of the crucial post-translational modifications that play an 
important role in biology. Ras superfamily of small GTPases is the largest protein family 
that undergoes post-translational prenylation for their biological role [1]. The prenylation 
of Ras has got immense interest when it is observed that oncogenic Ras are inactive on 
preventing from membrane attachment [2]. The protein prenylation, a process initiated by 
covalent attachment of 15-carbon farnesyl or a 20-carbon geranylgeranyl isoprenoids to a 
conserved cysteine residue, modifies many key regulatory proteins in eukaryotic cells at 
their C-terminus [3,4].  
The majority of these prenylated proteins are termed “CaaX proteins” due to their specific 
C-terminal motif that directs the lipid modification, which involves covalent addition of 
either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoids via thioether 
linkages to the conserved cysteine fourth in from their C-terminus. The enzymes 
responsible are termed as protein farnesyltransferase, (FTase, 15-carbon modification) and 
protein geranylgeranyltransferase-I (GGTase-I, 20-carbon modification). GGTase-I 
attaches the 20-carbon isoprenoid lipid to CaaX motifs wherein the carboxyl-terminal 
residue “X” is Leu or Phe) [4–6]. CaaX prenyl proteins, which include most members of 
the Ras family of GTP-binding proteins (G proteins), play critical roles in a number of 
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cellular processes, including transmembrane signaling, intracellular membrane trafficking, 
and mitosis [7,8].   
The protein prenylation cascade begins with the addition of a 15-carbon isoprene farnesyl 
lipid when X residues are Ser, Met, Gln, Cys, and Ala; or a 20-carbon geranylgeranyl lipid 
is added when the X residue is Leu [9]. The CaaX prenyltransferases include protein 
farnesyltransferase (FTase) that adds the 15-carbon farnesyl group to the cysteine residue 
of the CaaX sequence [4] whereas protein geranylgeranyltransferase type I (GGTase-I) 
transfers the 20-carbon geranylgeranyl group to proteins including critical signaling 
molecules from many classes, e.g., the Ras superfamily (including K-Ras, Rho, Rap, 
Cdc42, and Rac), several G-protein γ subunits, protein kinases (rhodopsin kinase, 
phosphorylase kinase, and GRK7), and protein phosphatases [4,10,11]. In addition to 
attachment of the isoprenoid, Ras and most other CaaX proteins undergo two subsequent 
prenylation-dependent processing steps, proteolytic removal of the -aaX tripeptide by the 
CaaX protease Ras converting enzyme (Rce1) and carboxymethylation of the now C-
terminal prenylcysteine residue by an enzyme termed isoprenylcysteine carboxy 
methyltransfrase (Icmt) [9, 12]. A schematic of the processing pathway for CaaX prenyl 
proteins is shown in (Fig. 1). The attached lipid imparts significant hydrophobic character 
to the protein, and can serve as an anchor for membrane association and as a hydrophobic 
determinant of protein-protein interactions.  
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Figure 1: Processing pathway for CaaX proteins 
 
Both Rce1 and Icmt are associated with the endoplasmic reticulum. The product of this 3-
steps modification process is to create a mature form of the CaaX protein with increased 
hydrophobicity that facilitates interaction with membranes; the modified C-terminus can 
also be viewed as a motif for specific protein-protein recognition events [13].   
The Ras proteins, the most thoroughly studied CAAX proteins, are mutated in human 
cancer more frequently than any other oncogenes. Because of involvement in the 
pathogenesis of many forms of cancer [14], Ras has been a center of focus for cancer 
biologist seeking to develop rationally designed anti-cancer drugs. Since isoprenylation is 
essential for the plasma membrane targeting of the Ras proteins and their ability to 
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transform cells [15], FTase inhibitors (FTIs) have been developed and tested as anticancer 
agents [16]. FTIs showed efficacy in preclinical studies of malignancies, including those 
without Ras mutations [17,18]. However, unfortunately, clinical trials of FTIs in humans 
have not been particularly successful [16]. 
1.2 The CaaX Prenyltransferases: FTase and GGTase-I 
As noted above, two distinct protein prenyltransferases act on CaaX-type proteins. FTase 
is a heterodimeric enzyme containing a 48 kDa  subunit and 46 kDa  subunit. GGTase-
I is similarly a heterodimer, with the same  subunit as FTase and a distinct 43 kDa  
subunit [19,20]. The enzymes use farnesyl diphosphate (FPP) and geranylgeranyl 
diphosphate (GGPP) as their respective isoprenoid substrates.  Proteins modified by FTase 
include the canonical Ras GTPases (H-, K- and N-), the nuclear protein lamin B, several 
proteins in the retina involved in phototransduction, and several enzymes controlling 
protein phosphorylation. Proteins modified by GGTase-I include GTPases in the Rho and 
Rac families, and many G protein  subunits.  The two CaaX prenyltransferases require the 
Cys residue fourth from the C-terminus of their protein substrates, with the X residue of 
the CaaX motif most responsible for which enzyme will act on the protein. When X is Ser, 
Met, Ala or Gln, FTase will process the protein, while if it is Leu then GGTase-I will 
handle; Phe seems to be efficiently recognized by both enzymes [11]. The simple 
tetrapeptide motif is the primary recognition; both enzymes can process CaaX tetrapeptides 
quite efficiently [14].  
The CaaX prenyltransferases are zinc metalloenzymes [21,22]. The kinetic mechanism of 
FTase has been extensively studied and is functionally ordered, with FPP binding first to 
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form a complex that reacts with a CaaX protein or peptide [23,24] GGTase-I appears to 
follow a similar kinetic mechanism [25,26].  The dissociation rate of the product very slow, 
and in vitro a FTase-product complex can be isolated [27,28]. Considerable structural 
information is available for both enzymes; FTase being the first to yield to the 
crystallography [29]. The common  subunit contains seven successive pairs of coiled-
coils that wrap around a significant portion of the  subunit, which is primarily helical and 
folded into an - barrel structure. Crystal structures of complexes containing both an 
isoprenoid analogue and a CaaX peptide bound in the active site revealed the determinants 
of the active sites both FTase and GGTase-I [30]. The availability of structural information 
on the CaaX prenyltransferases has allowed incisive structure-function analyses of the 
enzymes, and allowed structure-aided drug design. 
1.3 Structure of FTase and GGTase-I 
Including Ras, Rho and lamins more than 30 different types of farnesylated proteins, 
attachment of a 15-carbon farnesyl group to the cysteine residue of target protein by 
developing a thioether linkage (Scheme-1) [31], have been identified in the mammalian 
cells. As this farnesylation is essential for the membrane association and plays a critical 
role in transformation of normal cells to the cancer cells in mutant form of Ras. This 
process is catalyzed by a zinc metalloenzyme called as farnesyltransferase (FTase) [32–
34]. The studies show that FTase made of two different α and β subunits and for 
development of high level of FTase both subunits are indispensable. The apparent 
molecular weight measured by SDS-polyacrylamide gel electrophoresis is of 50 kDa. 
While by gel filtration chromatography is in range 70-100 kDa and also established the fact 




Scheme 1: Farnesylation of Cysteine in CaaX 
 
Hee-Won Park et al. produced FTase from Sf9 cell, purified and determined its crystal 
structure at 2.25 Å by applying different techniques like multiple isomorphous replacement 
(MIR) and anomalous scattering with three heavy atom derivatives, phase combination, 
solvent flattering and crystallographic refinement. The α-helices are the main components 
in the secondary structure between α and β subunits (Fig. 2 a&b). A series of right handed 
antiparallel coils formed by folding of 2 to 15 α subunits into seven successive pairs. These 
helical hairpins are arranged in a double layered, right handed super helix resulting in a 
crescent shaped subunit that envelops part of the β subunit. It is seen that all helices are 
parallel in one layer however they are antiparallel to helices in the adjacent neighboring 
layer. There are about twelve α helices of the β subunits which are folded in the form of α-
α barrel. From the figure 3a it is evident that the inner portion of the barrel is formed by a 
core of six parallel helices (3β, 5β, 7β, 9β, 11β, and 13β). However, the outside of the 
helical barrel is made up of six helices (2β, 4β, 6β, 8β, 10β, and 12β) that are inter connected 
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with the inner part. Thus the conclusion can be drawn that peripheral six helices are parallel 
to each other but antiparallel to other six helices. One ending of the barrel is blocked by a 
loop formed by residues 399β to 402β while the other end remains open for the solvent and 
form a cleft in the center where the active sites are present for enzymatic action [29].       
The β-subunit of FTase plays its role in binding of the peptide or protein substrate and 
prenyl donor in the presence of Zn2+. Prenylation product formation efficiently requires 
enzyme bound Zn2+ and high concentration of Mg+2 for protein farnesyltransferase [22].  
 
Figure 2a&b:  Crystal structure of the rat FTase heterodimer, with resolution of 2.25Å 
[29]. 
The crystal structure of FTase shows that zinc ion is located at a junction between 
hydrophilic surface near the subunit interface and a hydrophobic deep cleft in β-subunit 
that further lined with aromatic residue. This hydrophobic cleft at the center of α- α barrel 
is wrinkled with 10 highly conserved aromatic residues ((Trp (102β, 106β, 303β), Phe 
(253β, 302β), and Tyr (105β, 154β, 205β, 361β, 365β)). Directly opposite of zinc ion, at 
8 
 
the top of the cleft there is Arg202β in helix 7β is positioned in such a manner so that it 
might have interaction with the phosphate moiety of the substrate. The diphosphate moiety 
interacts with zinc atom only when the length of farnesyl diphosphate (FPP) is such that its 
terminal carbon of isoprenoid may bind at bottom of the packet (Fig. 3b). β subunit residues 
Asp297β and Cys299β residing in NH2 terminal flanking loop of helix 11β, His362β in 
helix 13β and water molecule contribute in the coordination of zinc. Where the bidentate 
ligand is formed by Asp297β and distorted pentacoordinate geometry is formed. Hua-Wen 
Fu et al. found that the mutation of Cys299β to Ala not only affects the binding of zinc but 
also leads to abolish catalytic activity [35].  
 
Figure 3 a&b: The β subunit (FT1). 
(a) Aromatic pocket in the center of the α-α barrel of the β subunit. Only helices 2β to 13β 
are shown. (b) A portion of the solvent-accessible surface showing some of the aromatic 
residues that line the putative FPP binding pocket (PDB: 1FT1) [35].  
Cross linking studies revealed that binding sites for the proteins and isoprenoid substrates 
located on the β subunit. The COOH terminal CaaX peptide and FPP substrates location 
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can be deduced from two clefts which are entirely different in surface properties and that 
intersects marked by bound zinc ion. The affinity of a protein substrate for FTase is 
enhanced by the presence of multiple basic residues just upstream of the CAAX motif (the 
so-called polybasic region) (Fig. 4a). 
Protein geranylgeranyltransferase type I (GGTase-I) is also zinc metalloenzyme where the 
prenylation leads to an addition of a 20-carbon isoprenoid group to the cysteine residue of 
CaaX motif. By using the CaaX motif as a substrate, the post translational modifications 
create lapidated domain that mediate attachment to specific proteins [33,36]. The zinc 
metalloenzymes (FTase/GGTase-I) are specific for the COOH- terminal residue however 
the GGTase-I prefer the proteins that have Leucine (Leu.) at terminal. Just like the FTase, 
GGTase-I is also a heterodimer of α and β subunits having the apparent molecular weight 
of 50 kDa. GGTase-I recognizes Leu. at the terminal of CaaX shares indistinguishable α 
subunits as far as FTase but differ entirely in β subunits that is crucial for selectivity of 
isoprenoid diphosphate substrate.  
J.S. Taylor et al. in 2003 presented the structural details for the mammalian GGTase-I along 
with series of substrate and product complexes that portray the path of chemical reaction. 
The structure was determined by single isomorphous replacement with anomalous 
scattering (SIRAS) method [26]. GGTase-I crystals belong to I222 space group, having 
three complete 91 kDa heterodimers in the asymmetric unit. The overall picture of the 
structure of GGTase-I is shown in figure 4b. In GGTase-I is found in crescent shape around 
β subunit of α subunits that are arranged to in α-helical hairpin pairs. The sequence of 
GGTase-I are identical to FTase α subunit , however, the crescent shaped α subunits of 
GGTase-I is slightly different by smaller in size (377 residues versus 437). There is an 
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extensive interface between α and β subunits covering more than 3300 Å.  A compact and 
globular α – α barrel domain having a central funnel shaped cavity is formed by β subunits 
where the substrate binding site opens. This cavity is lined by the hydrophobic residues. A 
zinc ion is also bound near the top of active site funnel cavity which is required for the 
catalytic functions [37]. Zinc ion can be removed by using chelating agents without altering 
the structure significantly. As α subunits are same in GGTase-I and FTase, so it can be 
presumed that the functional differences are the results of differences in β subunits having 
identity of only upto 25%. In GGTase-I a loop is formed by the residues 79β-121β 
connecting to helix 3β and 11β having an insertion of 26 residues relative to FTase. The 
loop ending at helix 4β that forms part of CaaX binding site and presents a shift in position 
to induce CaaX enzyme specificity.     
 
Figure 4: (a) Close-up view of the peptide binding cleft on the interface of the β subunit 
(PDB: 1FT1) (b) GGTase-I ternary substrate complex (PDB: 1N4P) [37]. 
Here, the GGTase-I consists of a 48 kD α subunit (red) and a 43 kD β subunit (blue). The 




portion of the KKKSKTKCVIL peptide substrate (yellow) binds against the isoprenoid, 
with the cysteine sulfur coordinating the catalytic zinc ion (magenta).  
1.4 Rationale for Targeting GGTase-I in Cancer 
The Rho-GTPases act as molecular switch for inactive GDP-bound form and an active 
GTP-bound state cycle. After activation of GDP-bound undergoes interaction with broad 
spectrum of diverse effectors to mediate their functions. Similarly another molecular 
switch for activation of GDP is guanine nucleotide exchange factors (GEFs) by catalyzing 
exchange of GDP to GTP. The most important investigated members of this group are K-
Ras, RhoA, Rac1, and Cdc42. Ras family members, particularly K-Ras, are major 
contributors to human tumorigenesis through mutational or other types of aberrant 
activation [38]. It is found that Ras mutations are responsible of ∼30% of most cancer types 
and so far identified it is included in mutated dominant oncogene. The discoveries of tumor 
suppressor functions for deleted in liver cancer 1 (DLC1) and Rho-GAP has provided 
evidence Rho GTPase activation is widespread in cancer as shown in figure-5 [37].  
 




In cancer progression, most deteriorating change is the switch from locally growing tumor 
to metastatic that involves numerous alterations to complete complex series of events 
required for metastasis. RhoC is a major contributor to metastasis of some solid tumors 
[39,40], and Ral proteins are activated in more than 90% of pancreatic duct 
adenocarcinoma cases [41]. The realization that many CaaX proteins, most notably Ras 
family members, are involved in pathologies such as cancer, inflammation and viral 
infectivity, has spurred efforts to develop inhibitors of CaaX processing as a rational 
approach to therapeutic development. The first prenyltransferase inhibitors were 
farnesyltransferase inhibitors (FTIs), which were rapidly developed from early CaaX 
peptide mimics [42] into the small organic ligands. The first peptidomimetic protein 
prenyltransferase inhibitors were mixed inhibitors, but highly selective inhibitors were 
rapidly developed. With the example of one of the canonical oncogenes H-Ras, rationale 
application of FTIs have shown efficacy in leukemias, gliomas, and breast cancers, 
providing the impetus for targeting GGTase-I in cancers driven by geranylgeranylated 
oncogenes [43,44]. However, FTIs have not performed up to expectation in solid tumors 
and failed to respond in many types of cancer, even those with activated Ras oncogenes 
[45–47]. The multifactorial nature of human cancers and “alternative prenylation”, a 
process whereby CaaX proteins including some Ras isoforms can be modified by GGTase-




Figure 6: Alternative prenylation by GGTase-I 
 
This cross-prenylation restores at least a portion of the activity [50]. Dual FTase/GGTase 
inhibitors have received little attention, and this type of treatment would impact a large 
number of proteins, which make resulting interpretations complicated. As a result several 
GGTIs have been developed that inhibit C20 lipid modification of GGTase-I substrates. 
Even though GGTIs have been primarily developed for use as cancer therapeutics, 
particularly in cancers that have high levels or activating mutations of geranylgeranylated 
proteins [9,51] they are now receiving broad interest for clinical use. Besides the continuing 
development as anticancer agents, GGTIs are now postulated to have a potential in treating 
a wide array of other diseases including inflammation, multiple sclerosis, atherosclerosis, 
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viral infection (HepC/HIV), apoptosis, angiogenesis, rheumatoid arthritis, psoriasis, 
glaucoma, and diabetic retinopathy [37,52]. In addition, nonhuman selective GGTIs have 
been developed as antifungals and antiparasitics since GGTase-I function is a prerequisite 
in the normal functioning of many parasites and fungi [53,54]. 
Additionally, a number of CaaX proteins such as Ras, Rho, Rac, and Cdc42 that are 
substrates for GGTase-I are intimately involved in tumorigenesis [13]. Administration of 
GGTI to cells has been reported to cause cell cycle arrest at G0/G1 by inactivation of 
cyclin-dependent kinases that act downstream of Rho [55, 56]. Studies have revealed that 
GGTIs stimulate apoptosis in multiple cell lines [57–59]. Inhibition of GGTase-I 
administration resulted in tumor regression in mouse xenograft models of breast cancer 
with evidence of impact on the afore-mentioned cyclin-dependent kinases [60]. Hence, 
besides their potential impact on oncogenesis, GGTIs have been proposed as potential 
drugs for anti-angiogenic therapy and for inhibiting metastatic progression of cancers 
[13,61].  An impact on Rho proteins, specifically RhoA and RhoC, is most often cited as 
the way in which GGTIs impact the metastatic phenotype, but recently and “orphan” 
protein termed C17orf37 has also been implicated.  This protein was shown to be modified 
by GGTase-I, and its ability to increased cellular migration was shown to be dependent on 
prenylation [62]. Ectopic expression of C17orf37 modulated the dissemination of cancer 
cells and facilitated formation of metastatic nodules in a mouse model of metastasis.  
Glioblastoma multiform represent the most common malignant intracranial tumors, which 
are characterized by rapid proliferation, poor prognosis, and resistance to traditional 
therapeutic approaches [63]. In a recent study the expression level and functional 
significance of GGTase-I in human malignant glioma was investigated [64]. GGTase-I 
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levels in glioma were found to be significantly elevated compared to normal brain tissue. 
Knockdown of GGTase-I using siRNAs targeting the β subunit, or treatment with GGTI-
2147, markedly decreased the association of RhoA and Rac1 with the plasma membrane 
and the activation of Rac1; these data were consistent with previous reports in breast cancer 
and lung cancer cells [65,66]. The glioma study concluded that geranylgeranylation of 
Rac1 was an important step in glioma cell growth, and that enhanced GGTase-I activity in 
the cancer may be important in its development.  
Genetic targeting of GGTase-I mice has also provided strong evidence supporting GGTase-
I as a drug target. Conditional knockout of the enzyme reduced the number and growth of 
tumors, and increased survival, in mice with lung cancer induced by mutant K-RAS [67]. 
In sum, these findings have spurred efforts to develop inhibitors of GGTase-I for evaluation 
as therapeutics, either on their own or in combination with FTIs. 
In FTI-treated cells, K-RAS and N-RAS are alternately prenylated by GGTase-I [49] and 
as a result the research community was prompted to develop GGTase-I inhibitors (GGTIs) 
[52]. GGTIs have shown promise in preclinical studies [66,68,69] and the rationale for 
inhibiting GGTase-I is supported by genetic studies in mice: Inactivating the gene for the 
β-subunit of GGTase-I (Pggt1b) reduced tumor formation and prolonged survival in mice 
with K-RAS-induced lung cancer [67]. An important role for geranylgeranylated proteins 
such as Rho in cell regulation, and their aberrant activation diseases, is increasingly being 
documented [70,71]. Rho proteins stimulate signal transduction pathways that induce 
cytoskeletal and transcriptional responses through diverse effectors. Dysregulation of the 
Rho pathway is implicated in multiple pathological conditions including cancer, in 
particular metastatic progression, cardiovascular disease, hepatic disease, and 
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developmental disorders. In this light, the interest in targeting these proteins has increased. 
Rho activity has a clear function in angiogenesis [61], which in turn plays a critical role in 
the pathogenesis of tumors, rheumatoid arthritis, atherosclerosis, psoriasis, and diabetic 
retinopathy [72]. In multiple sclerosis, infiltration of leukocytes and monocytes into the 
central nervous system as part of an inappropriate inflammatory response leads to 
demyelination of axons and nerve damage, resulting in motor and cognitive impairment.  
Recent evidence suggests that this migration requires Rho signaling and inhibition of 
prenylation can lead to decreased disease progression [73,74]. Additionally, the replication 
of hepatitis C virus in liver cells requires a GGTase-I substrate, and evidence indicates that 
replication of hepatitis C virus can be attenuated by inhibiting geranylgeranylation, 
providing a potential new therapeutic prospect for this increasingly prevalent disease 
[75,76]. 
1.5 Inhibition of GGTase-I 
1.5.1 Inhibitors of GGTase-I 
Over the last 20 years a wide variety of GGTIs have been reported in various publications 
in the relatively short time when the enzyme has been studied. Many of these have been 
designed rationally on the basis of the substrates of GGTase-I: geranylgeranyl diphosphate 
(GGPP) or the CaaX peptide. There are also a number of natural compounds that were 
identified in a screen for inhibition of GGTase-I from Candida sp. A comprehensive review 
of known GGTIs was published recently [52]. Unfortunately, many of the known binding 
modes of GGTIs were never characterized and IC50 data for the same compounds are often 
in disagreement when measured by different laboratories. These observations make the 
large portion of GGTIs less than optimal for quantitative structure-activity relationship 
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(QSAR) model building. However, there are two known scaffolds that have been well 
characterized with respect to their binding to the peptide pocket and using similar estimates 
for IC50 values. These include a number of CaaL (L represents leucine) peptidomimetics 
including aminobenzoic acid derivatives such as GGTI-298 and GGTI-2154 [56,77] and 
benzoyleneurea-based compounds [78]. More recently three newer classes of GGTIs have 
been published including one based on a piperazin-2-one backbone [79], 
dihydropyrole/tetrahydropyridine based small molecules [80], and allenoate compounds 
[81]. As geranylgeranyltransferase inhibitors (GGTIs) aminobezoic acid derivatives were 
synthesized following C-terminal CaaL peptidomimetic sequence. Here, 2-aryl-4-
aminobenzoic acid moieties were used as mimetics for central two amino acids dipeptide 
(aa). While the cysteine part was replaced with imidazole and pyridine derivatives at N-
terminus. The absence of cysteine in the structure made these molecules non thiol 
peptidomimetic compounds for exceptional selective inhibition of GGTase-I instead of 
FTase [77]. Another aminobenzoic acid derivative was GGTI-298 that showed inhibition 
of GGTase-I led to arrest of G0/G1 in fibroblasts [56].  
Similarly, the aa part of CaaX tetrapeptide was replaced by benzoyleneurea scaffold by 
Carrico et.al. These novel compounds were found potent and selective inhibitors of 
GGTase-I. Further, it was found that compounds having free carboxylic functionality were 
more potent and compounds having L-configured phenylalanine possess high affinity to 
bind the hydrophobic X specificity pocket of enzyme [78]. A semi-rigid scaffold of 
piperazin-2-one were synthesized as mimic the CaaL sequence. The potency of the GGTIs 
was based on the presence of L-leucine residue having free carboxylic acid as well as the 
S configuration of the 3-aryl groups. While upon substitution of 5-methyl on imidazole and 
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fluorine on 3-aryl group attributed for enhanced selectivity [79]. Castellano et al. 
synthesized dihydropyrrol and tetrahydropyridine heterocyclic compounds via allene 
phosphine catalysis and used them as GGTIs. From the screening of 4288 analogues, only 
two compounds showed the IC50 in submicromolar [80]. Same kind of heterostructural 
moieties allenoate derived compounds were synthesized and tested for GGTase-I 
inhibition. It was observed that derivatization of carboxylic acid originating from the core 
improved the cellular activity, inhibition of proliferation of human cancer cell lines, 
induction of p21CIP1/WAF1 and G1 cell cycle arrest  [81].   
1.5.2 Current Status of GGTase-I Inhibitor Development-literature survey 
The results of the detailed studies prompted both pharmaceutical companies and academic 
laboratories to develop GGTIs [52,55,66,82]. Several GGTIs have been developed, with 
peptidomimetic-based GGTIs being the largest class to date and include aminobenzoic 
acid-containing compounds such as GGTI-298 and GGTI-2154 [77,83], and compounds 
containing benzoyleneurea [78]. In this regard, tetrapeptide-based bivalent inhibitors were 
developed based on structural data for GGTase-I that simultaneously targeted multiple 
protein surfaces [84]. All of these bivalent inhibitors exhibited great selectivity for 
GGTase-I over FTase and the inhibitory ability of these compounds was improved 
compared to simple tetrapeptide. One compound targeting GGTase-I has advanced to 
clinical trial [13], although little information is yet available on the results.    
In addition to synthetic design of substrate analogues and high-throughput screening to 
identify compounds, computational design of small molecule inhibitors targeting GGTase-
I has begun to bear fruit. Recently, a computation-based 3-D model for human GGTase-I 
to which a small molecule library was virtually docked using a program termed AutoDock 
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Vina has revealed that natural compounds camptothecin and curcumin exhibited higher 
virtual binding affinities to GGTase-I than that of established peptidomimetic GGTIs [85]. 
Camptothecin is a well-known topoisomerase I inhibitor and anti-cancer drug [86], while 
curcumin is a pleiotropic molecule that has been shown to impact cancer regression in a 
number of ways [87]. Based on a number of observations, it was hypothesized that anti-
cancer activity of these compounds might in part be due to GGTase-I inhibition, but direct 
experimental validation of this hypothesis is still lacking. A computational approach 
involving Quantitative Structure Activity Relationship (QSAR) models of known GGTIs 
has also led to new scaffolds with inhibitory activity being identified [88], but the activities 
were rather low and the compounds have not yet been further refined. 
A compound termed GGTI-2Z was recently reported to block prenylation process 
catalyzed by both GGTase-I and RabGGTase (a related enzyme that specifically prenylates 
most Rab GTPases) [89]. The efficacy of GGTI-2Z was augmented by co-administration 
of a statin and strongly correlated with the ability to induce autophagy. Another compound, 
GGTI P61A6, showed strong inhibition of tumor growth in a mouse xenograft of pancreatic 
cancer [82]. In another discovery effort, small molecule inhibitors of GGTase-I identified 
in a library of allenoate-derived compounds were reported to inhibit proliferation and 
trigger cell cycle arrest of a number of cell lines, including leukemic, pancreatic, and breast 
cancer cell lines [81]. A GGTI termed P61-E7 containing a tetrahydropyridine scaffold has 
recently been described that inhibited proliferation and impaired cell cycle progression 
[90]. In addition, P61-E7 impacted processes controlled by cyclin-dependent kinases, and 
P61-E7 treatment of Panc-1 cells impacted the organization of the actin cytoskeleton and 
assembly of focal adhesions.  
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The impact of GGTIs on the prenylation of a number of small GTPases in oral squamous 
cell carcinoma (SCC) was recently investigated [91]. GGTI-298 treatment resulted in 
mislocalization of RhoA, leading to increased p21Waf1/Cip1 level and G1cell cycle arrest, 
and affected RalB with subsequent impairment of migration and invasion of SCC cells. 
The impact of GGTIs on the early events associated with metastasis, specifically the 
organization of the cytoskeleton and the importance of this process in invasion and 
migration, has also been investigated [92]. The study revealed that GGTI treatment 
impaired the migration and invasion of PC-3 cells, consistent with an earlier similar study 
on human pancreatic cancer cells [93]. A list of recently developed GGTase-I inhibitors is 
given in table 1. A comprehensive list of previously discovered GGTase-I inhibitors has 
also been detailed elsewhere [52].   
Table 1: Inhibitors of GGTase-I. 










































































































































































































120 µM  [66] 
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Despite of good antiproliferative and pro-apoptotic properties FTIs and GGTIs both invitro 
and in vivo, these compounds became problematic at clinical stage due to toxicity. To avoid 
the toxicity of these inhibitors, a new strategy for simultaneous inhibition of FTase and 
GGTase-I (Dual Prenylation Inhibitors, DPIs) was adopted (Table 2) [96]. This approach 
was evaluated after observing the synergistic inhibition of FTase and GGTase-I 
simultaneously on various tumor cell lines. More than 70% growth inhibition was seen in 
myeloid cell lines where apoptosis was induced by GGTI-286, GGTI-298, GGTI-2147 and 
FTI L-744,832 inhibitors. Thus co-treatment of FTIs and GGTIs led to synergistic 
cytotoxic effects in primary acute myeloid leukemia (AML) cell lines and myeloid cells 
[58]. A dual inhibitor of FTase and GGTase-I having geometry of CaaX peptidomimetic 
sequence, L778,123, was tested. Due to significant inhibitory potential L778,123 was 
tolerated for phase I and II clinical trials and was able to reduce prenylation of Rap1a and 
HDJ2 except K-Ras. But QT-prolongation was observed in all trials of L778,123 [58]. 
26 
 
Another DPI was AZD3409 also well tolerated for initial phases of trials and showed 
significant inhibition of tumor growth. The positive aspects demonstrated were no change 
in heart rate and electrocardiogram recording but the adverse effects of orthostatic 
hypertension, paranesthesia, nausea diarrhea and dizziness have been noticed [97]. Further 
studies showed that AZD3409 as DPI inhibits more FTase as compared to GGTase-I and 
from its radio sensing, it was found that this drug did not inhibit prenylation in case of K-
Ras. Similar situation was happened for L778,123 DPI where it inhibited the Rap1A 
prenylation but not the K-Ras. Thus, even the use of DPI could not resolve or overcome 
the issues of toxicities and complete inhibition of prenylation process.  
Other than DPIs, the problems of toxicities caused by individual treatment of FTase and 
GGTase were avoided using the following two possible plans; one is the synergistic activity 
of mevalonate and potent prenyl inhibitors, e.g. the synergistic activity in combinations of 
FTIs and statins or isoprenoids or bisphosphonates has been studied, and second is the 
synergistic activity of conventional chemotherapy and radiotherapy. Morgan et al. found 
that FTI/statin combinations inhibit more effectively the prenylation modifications via 
decreasing isoprenoid level. The myeloma cells underwent apoptosis and reduced cell 
migration, where FTIs enhanced the lovastatin ability to inhibit Rho, K-Ras, N-Ras 
prenylation and activation of MEK/MAPK. The synergistic effect of FTI/statin 
combinations also led to reduce use of doses as compared to individual implications. While 
statin/isoprenoid combinations also induced the synergistic inhibition of growth of human 
















1.5.3 Future Directions for GGTIs development 
The initial emphasis on development of GGTIs was as anticancer agents. However, the 
activities of Rho proteins, among the major targets of GGTIs, are also important for the 
ability of macrophages and other inflammatory cells to migrate and to respond to stimuli 
that trigger an inflammatory response [100]. Given that dysregulation of the Rho pathway 
is implicated in multiple pathological conditions beyond cancer, for example 
cardiovascular and hepatic disease, and several developmental disorders, it seems that 
GGTIs can be considered for applications beyond cancer. In addition, Rho activity has a 
clear function in angiogenesis [61], which in turn plays a critical role in the pathogenesis 
of tumors, rheumatoid arthritis, atherosclerosis, psoriasis, and diabetic retinopathy [72]. In 
multiple sclerosis, infiltration of leukocytes and monocytes into the central nervous system 
as part of an inappropriate inflammatory response leads to demyelination of axons and 
nerve damage, resulting in motor and cognitive impairment. Recent evidence suggests that 
this migration requires Rho signaling and inhibition of prenylation can lead to decreased 
disease progression [73,74]. Consequently, GGTase-I inhibition presents a viable strategy 
to impair the pro-inflammatory activities of Rho GTPases and potentially treat of 
inflammatory disorders, including atherosclerosis and multiple sclerosis [101–103].  
There have been many reports on beneficial effects of statins not linked to their lipid-
lowering properties, and in many cases these effects have been linked to the inhibition of 
protein geranylgeranylation [101,104,105]. Statins block the production of mevalonate, 
and hence also the downstream metabolites FPP and GGPP [9]. However, it has been 
recently demonstrated that conditional knockout of GGTase-I in macrophages resulted in 
accumulation of GTP-bound active RhoA, Rac1, and Cdc42 [106], leading to increased 
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production of pro-inflammatory cytokines and rheumatoid arthritis in mice. These results 
suggest that geranylgeranylation might restrain, rather than support activity of Rho proteins 
in macrophages. The study revealed that GGTase-I deficiency in macrophages markedly 
reduces atherosclerosis despite higher levels of inflammation and development of 
rheumatoid arthritis. This was a bit surprising, as increased inflammation is generally 
associated with increased atherosclerosis rather than the opposite. While these results are 
all quite intriguing, it remains unclear precisely what is happening in the mouse models of 
GGTase deficiency in lymphoid cells. 
A number of fungal and protozoan pathogens express CaaX proteins that are important for 
virulence and/or survival, and the FTase and GGTase-I have therefore been proposed as 
targets for treating infectious diseases. The replication of hepatitis C virus in liver cells 
requires a GGTase-I substrate, and replication of hepatitis C virus can be attenuated by 
inhibiting geranylgeranylation [75,76]. Cryptococcus neoformans (C. neoformans), a 
pathogenic fungus that severely affects immunocompromised people, has become a major 
health problem because of the prevalence of HIV and the use of immunosuppressive drugs 
following organ transplant. The function of the C. neoformans Ras1 (CnRas1) GTPase 
requires processing of its C-terminal CaaX motif, and the Ras1 and Ras2 proteins of C. 
neoformans are predicted to be GGTase-I substrates [107]. Further, the C. neoformans 
GGTase-I is required for the prenylation of Cdc42 and Rho10 in the organism [108], and 
these two proteins are important for the growth of this pathogenic fungus. Knockout of 
GGTase-I dramatically reduced virulence in an animal model of C. neoformans infection, 
although some compensatory farnesylation was detected that prompted a suggestion that 
the CaaX motif may not dictate all specificity for prenylation in this organism. The 
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structure of the GGTase-I from Candida albicans (CaGGTase-I) has been solved [109], 
and close inspection of the active site revealed areas of significant divergence in critical 
regions from the mammalian orthologue. These unique structural features of the Candida 
GGTase-I could provide opportunities to design selective inhibitors for the development 
of new anti-fungal therapeutics.  
In brief, the physiological significance of protein geranylgeranylation has been highlighted 
in recent studies. The GGTase-I deficiency has been implicated in proliferation inhibition 
and accumulation of p21CIP1/WAF1 and reduction of the oncogenic K-Ras-induced lung 
tumor formation in mice [67]. Moreover, geranylgeranylated proteins such as Rho, Rac 
and Cdc42 have been linked to tumorigenesis and metastasis [110–112]. In addition, GGTI 
can cause cell cycle arrest at G0/G1 [55,113], stimulate apoptosis in multiple cell lines 
[57,59] and geranylgeranylation inhibition was found to regress breast tumor xenografts in 
vivo [60]. The implications of geranylgeranylated proteins in oncogenesis have highlighted 
the potential for GGTase-Is as the potential chemotherapies [5,114]. Consequently, 
different strategies have been explored to develop GGTIs [115], including peptidomimetic 
and small-molecules inhibitors [81,89]. 
Peterson et al. described the characteristics of a highly selective and potent GGTase-I 
inhibitor, GGTI-DU40. The kinetic studies of GGTI-DU40 demonstrated competitive 
inhibition with the protein substrate but uncompetitive inhibition with isoprenoid substrate 
where Ki = 0.8 nM. GGTI-DU40 was able to block the prenylation of a number of 
geranylgeranylated CaaX proteins selectively in vitro as well as in living cells. Further 
treatment of breast cancer cell lines (MDA-MB-231) by GGTI-DU40 was manifested by 
inhibition of thrombin-induced cell rounding through a process called Rho proteins 
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inhibition. Thus, GGTI-DU40 was established as a prime evidence for studying protein 
geranylgeranylation and a novel class of therapeutics. Driven by the limited bioavailability 
associated with its hydrophobicity of a potent and selective inhibitor of GGTase-I (GGTI-
DU40) both in vitro and in living cells, we were motivated to design a series of substituted 
pyrazoles 2-16 (Fig. 7) [66]. Herein, we wish to disclose the synthesis and biological 
evaluation of compounds 2-16 and molecular docking studies of the most active compound 
2 in the series.  
 





3 CHAPTER 2 
Research Objectives and Work Plan 
2.1 Research Objectives 
The objectives of this designed research study are as following; 
1. The limited bioavailability and hydrophobicity of highly potent and selective inhibitor 
of GGTase-I (GGTI-DU40), motivated us to synthesize structural analogues of GGTI-
DU40, compounds 2-16 (Fig. 8), in order to improve its drug like profile.  
2. In vitro screening of 2-16 against the purified enzymes (GGTase-I and FTase).  
3. Analysis of cellular activity of 2-16 against cancer cells lines (MDA-MB-231 breast 
cancer cells). 
4. Establishment of structure activity relationship (SAR) studies of compounds 2-16. 
 
Figure 8: Chemical structures of target compounds 2-16 
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2.2 Methodology and Work Plan 
2.2.1 Synthesis of Target Compounds (2-5) 
The synthesis of target compounds (2-5) would necessitate the synthesis of amino acids-
derived amides (25-28) (Fig. 9), which in turn would be accomplished as outlined in 
scheme-2. 
 
Figure 9: Amino acids-derived amides (25-28) 
The esterification of amino acids 17-19 would produce the corresponding hydrochloride 
amino esters 20-22 [116–118]. Similarly, the acid induced deprotection of boc group of 
ester 23 [119] would generate amino ester 24 [120]. Moreover, condensation of amino 
esters 20-22 and 24 with ammonium hydroxide in a pressure vessel, would furnish the 
desired α-amino amides 25-28, respectively (scheme-2).  
 
Scheme 2: Synthesis of amino acid derivatives 25-28 
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With suitably modified amino acids in hands, we would next move to access the synthesis 
of 49, a key intermediate needed to accomplish the synthesis of 2-5 (Scheme-3). To this 
end, cross Claisen reaction of ethylnicotinate 45 with γ-butyrolactone using sodium 
ethoxide as base would produce α-ketobutyrolactone 46, [121] which in turn would be 
condensed via Knorr pyrazole synthesis reaction with 3,4-dichlorophenylhydrazine 
hydrochloride in acetic acid to generate pyrazole 47 [122]. Whereas the O-alkylation of 47 
with ethyl 4-bromobutanoate in DMF would construct pyrazole ester 48 [122], which will 
be exposed to basic condition to remove the acetyl protection to produce the desired 
intermediate 49. The target compounds 2-5 could be ensued from 49 by the amidation of 
49 with amino acid amides 25-28 to generate pyrazole amides 50-53 followed by the 
mesylation of the resultant intermediates 50-53 and condensation with sodium 




Scheme 3: Synthesis of 2-5 
Alternatively, selective basic hydrolysis of 48 would produce alcohol 49. The latter can be 
exposed to the operations of msylation and condensation with sodium methanethiolate to 
produce the corresponding thioethers. Moreover, the amidation of thioethers with amino 




Scheme 4: Alternative way for synthesis of 2-5 
2.2.2 Synthesis of Target Compounds (6-16) 
The synthesis of reverse amides 6-16 analogues of GGTI-DU40 would require access to 
the modified amino acids intermediates 29-32 and advanced intermediate 58. To this end, 
amino acids 29-32 could be converted directly into corresponding N-acetylated amino 
acids 33, 35, 37 and 39 and N-acylated amino acids 34, 36, 38 and 40 by the action of 
acetylation or mesylation, respectively (Scheme-5).  
 




Alternatively, the synthesis of amino acid derivatives 33-40 could be also be ensued from 
the esterification of amino acids 29-32, N-acetylation or N-acylation followed by basic 
hydrolysis (Scheme-6).  
 
Scheme 6: Alternative way for synthesis of 33-40 
Likewise, L-tyrosine ester hydrochloride 41 would be converted to its corresponding N-
acetylated or N-acylated derivatives 42-44 by employing previously-reported procedures 
(Scheme-7) [123,124].  
 
Scheme 7: Synthesis of amino acid derivatives 42-44 
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On the other hand, the synthesis of the advanced intermediate 58 and subsequent synthesis 
of the target compounds 6-16 could be ensued as outlined in scheme-8. The O-alkylation 
of pyrazole 47 with tert-butyl (3-bromopropyl)carbamate would construct the desired 
intermediate 54, which in turn would be subjected to basic hydrolysis to produce alcohol 
55. Mesylation of 55 would construct 56, which upon condensation with sodium 
methanethiolate would furnish the thioether 57. The deprotection of Boc with acetyl 
chloride in MeOH can produce the desired advanced intermediate 58. The amidation of the 
latter with 33-40 and 42-44 would finally render access to 6-16 (Scheme-8). 
 
Scheme 8: Synthesis of 6-16 
2.3 Pharmacological screening of synthesized compounds (2-16) 
All the synthesized compounds will be tested for their ability to inhibit GGTase-I in vitro 
and in cancer cells to determine IC50 values for impact on the signaling pathways controlled 
39 
 
by protein geranylgeranylation. The potential anti-cancer compound will also be tested for 
antiproliferative activity, which would involve cell proliferation assays, as well as 
assessment of the activity of key signaling pathways controlling cell growth (MAP kinase, 




4 CHAPTER 3 
RESULTS and DISCUSSIONS 
3.1 Chemistry  
The synthesis of compounds 2-16 necessitated the preparation of suitably modified amino 
acid derivatives. As outlined in scheme-9 esterification of amino acids 17-19 produced the 
corresponding amino esters 20-22 [116–118]. Likewise, acid induced removal of Boc 
protection of ester 23 [119] produced the amino ester 24 in 98% yield [120]. Moreover, 
reaction of amino esters 20-22 and 24 with ammonium hydroxide in a pressure vessel 
heating at 100 oC overnight furnished the desired α-amino amides 25-28 in good to 
excellent yields (85-95%) [125]. 
 
 
Scheme 9: Synthesis of amino acid derivatives 25-28 
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Similarly, L-phenylalanine was transformed to the known 33 [126] and 34 [127]. Likewise, 
amino acids 14-17 were first transformed to their corresponding methyl esters 18-21 by the 
action of thionyl chloride in methanol. The N-acetylation or N-acylation of 18-21 with 
acetyl chloride or methane sulfonyl chloride followed by basic hydrolysis with LiOH 
furnished the desired intermediates 33-40. Even though this route provided straightforward 
access to the intermediates 35 and 36 in a moderate overall yield of (64%) and (61%), 
respectively, the transformation of 20 and 21 to their corresponding 37-40 was low yielding 
(36-41%). In the latter case, the basic hydrolysis step resulted fewer side products. In 
addition, the higher water affinity of 37-40, made their extraction difficult from the aqueous 
workup (Scheme-10). 
 
Scheme 10: Synthesis of amino acid derivatives 33-40. 
Consequently, a direct route for the preparation of intermediates 33-40 was envisioned. 
The acetylation of 18 and 19 with acetic anhydride in MeOH under reflux followed by 
evaporation of the solvent and aging the obtained residues overnight in a refrigerator 
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rendered 33 and 35 in excellent yield (81-86%). Under identical conditions, the acetylation 
of 20 and 21 produced the corresponding 37 (73%) and 39 (75%) in high yields. Similarly, 
the acylation of 18 and 29 with methane sulfonyl chloride in a mixture of dichloromethane 
and 1M NaOH furnished 34 and 36 in good yield (80-81%). By adopting similar synthesis 
strategy, amino acids 20 and 21 were also transformed to the corresponding desired 
intermediates 38 and 40 in high yields (Scheme-11). 
 
Scheme 11: Alternative synthesis of amino acid derivatives 33-40 
Likewise, an ester intermediate 41 was transformed to the known 42 [118] by the 
operations of N-acetylation of the amine function with acetic anhydride, O-alkylation of 
phenolic hydroxyl group with iodomethane and then basic hydrolysis of ester moiety with 
LiOH [123]. In addition, 43 [119] was produced from 41 from the reactions sequence of 
N-acylation with di-tert-butyl dicarbonate (boc anhydride) followed by O-alkylation of 
hydroxyl group with iodomethane and finally basic hydrolysis of ester group [124]. On the 
other hand, N-acylation of 41 with methane sulfonyl chloride in dichloromethane followed 
by O-alkylation of phenolic hydroxyl moiety with iodomethane furnished intermediate in 
a high yield (83% for two steps). The basic hydrolysis of that with LiOH in a mixture of 
water, methanol and THF finally produced the desired 44 [117] in 68% overall yield from 






Scheme 12: Synthesis of amino acid derivatives 42-44 
With suitably modified amino acids in hands, we next moved to access the synthesis of 
target compounds 2-5 (Scheme 13). To this end, ethyl nicotinate 45 was treated via cross 
Claisen reaction with γ-butyrolactone in ethanol, using sodium ethoxide as a base to 
produce α-ketobutyrolactone 46 [121]. Knorr pyrazole synthesis condensation of 46 with 
3,4-dichlorophenylhydrazine hydrochloride in acetic acid produced the pyrazole 47 [122]. 
The O-alkylation of 47 with the ethyl 4-bromobutanoate in DMF furnished the pyrazole 
ester 48 [122], which was subjected to the basic hydrolysis using LiOH in a mixture of 
H2O, MeOH and THF to remove both the acetyl and ester moieties, generating intermediate 
49 [122] in 42% overall yield from 47. Next, amidation of intermediate 49 with amino 
amides 25-28 in a mixture of CH2Cl2 and DMF, using N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride and N-hydroxybenzotriazole as coupling agents 
furnished the corresponding pyrazole amides 50-53 in good yields (Scheme-13). It is worth 
mentioning that we first attempted to deacetylate 48 by employing  milder basic condition 
(K2CO3, MeOH) to produce the corresponding hydroxy ester (R1 = Et; R2 = H). The latter 
was intended to be transformed to the corresponding thiomethyl ether carboxylic acid, a 
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thioether analogue of 49 (R1 = H; R2 = SCH3), by the sequence of mesylation of alcohol, 
condensation with sodium methanethiolate and basic hydrolysis of the ester function. 
However, the deacetylation of 48, unfortunately, had led us to an undesired side product 
that had lost the O-acetyl and ester moieties, as evident from the 1H-NMR and IR spectra. 
Nevertheless, mesylation of intermediates 50-53 with MsCl in CH2Cl2 followed by 
condensation of the resultant mesylate with sodium methanethiolate in DMF produced the 




Scheme 13: Synthesis of 2-5 
 
On the other hand, the synthesis of compounds 6-16 was ensued as outlined in Scheme-14. 
In brief, the O-alkylation of pyrazole 47 with tert-butyl (3-bromopropyl)carbamate in DMF 
at room temperature constructed the desired intermediate 54 which was in turn subjected 
to basic hydrolysis to produce alcohol 55. Mesylation of 55 constructed 56, which was 
condensed with sodium methanethiolate in DMF to furnish the thioether 57. The acid-
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induced removal of Boc protection with acetyl chloride in MeOH produced the desired 
primary amine 58 in 64% overall yield from 54 (Scheme-14). The amidation of the primary 
amine 58 with 33-40 and 42-44 finally rendered access to 6-16 in moderate to good yields 
(57-69%). 
  




3.2 Biological results 
3.2.1 GGTase-I and FTase assays 
All the synthesized compounds (2-16) were screened for in vitro inhibition against 
recombinant purified GGTase-I (Fig.10) and FTase, using GGTI-DU40 (1) and FTI-277 
as positive controls, respectively. The screening results are summarized in table 3 and 
figure 10. In case of GGTase-I inhibition, a clear trend of decreased inhibitory activity for 
propanamides (6-16), derived from the coupling of propanoxypyrazole propanamine with 
suitably modified amino acid derivatives, compared to butanamides (2-5), originated from 
the reaction of propanoxypyrazole butanoic acid with α-amino amides, was clearly 
observed. Compound 11 (IC50 = 9.9 µM) that bears 4-methoxyphenyl ring on the amino 
acid turned out to be the most active in the propanamide series. However, the activity was 
diminished to more than three-fold when the N-methylsulfonamido moiety of 11 was 
substituted with an acetamido moiety, producing 10 (IC50 = 34.8 µM). The influence of N-
methylsulfonamido group in the enhanced activity of the propanamide series was further 
evident when the activity of 9 (IC50 = 19.7 µM), possessing 4-fluorophenyl ring on the 
amino acid, was slightly reduced compared to its acetamido counterpart 8 (IC50 = 26.3 
µM). Moreover, comparison of inhibitory activities of 9 with 11 revealed that the 4-
methoxyphenyl on amino acid is more crucial compared to the corresponding 4-
methoxyphenyl moiety. In fact the activities of propanamides were totally lost or 
diminished significantly when the combination of either 4-methoxyphenyl or 4-
fluorophenyl on amino acid and the N- methylsulfonamido group was absent. For instance, 
whereas compounds 6 (IC50 = 22.9 µM), 7 (IC50 = 31.9 µM), 15 (IC50 = 26.9 µM) and 16 
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(IC50 = 19.0 µM) had moderate activities, compounds 12-14 turned out to be completely 
inactive (Table-3). 
It is apparent that, in general, the nature of linker between the pyrazole moiety and the 
amino acid played a significant role in the activities of 2-5 compared to 6-16. Compound 
2 (IC50 = 2.4 µM) that was produced by incorporating the fluoro group at C-4 of phenyl 
ring of  amino acid of 1 turned out to be the most active in the series, showing higher 
activity than 1 (IC50 = 3.3 µM). An earlier report has suggested that placing fluorine at C-
4 of phenyl ring has significantly enhanced the activity of a thrombin inhibitor compared 
to when it was present at other positions of phenyl ring. This high potency was attributed 
to the dipolar C–F…H–Cα and C–F…C=O interactions between the 4-fluorophenyl ring 
and the enzyme’s active site [128]. The role of 4-fluorophenyl ring in the high potency of 
compound 2 was evident with the observation that when it was replaced with pyridyine-3-
yl or pyridyine-4-yl group to produce 3 (IC50 = 11.6 µM) and 4 (IC50 = 7.8 µM), 
respectively, the activity was diminished to 5 and 3-fold, respectively. In contrast to our 
observation in propanamide series, where the 4-methoxyphenyl ring on the amino acid was 
more effective compared to the 4-fluorophenyl ring (11 vs 9), comparison in the 
butanamide series revealed that compounds with 4-fluorophenyl ring was relatively more 
active compared to its 4-methoxyphenyl counterpart (2 (IC50 = 2.4 µM) vs 5 (IC50 = 3.1 
µM)). This suggested that electronegative fluoro or methoxy groups attached to C-4 of 
phenyl ring of amino acid may play an important role in the interaction with the active site 
of enzyme. All target compounds 2-16 were also tested for in vitro inhibition against 
recombinant purified FTase enzyme, using inhibitor FTase-277 as control. The screening 
results, summarized in table 3, revealed that compounds 2-16 do not show any activity at 
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100 µM concentration which suggested that these compounds are selective inhibitors of 
GGTase-I. 
 








Table 3:  In vitro GGTase-1 and FTase activity, impact on GTPase Rap1A and MTT assay 
of compounds 2-16 
 
a Each measurement was performed as triplicate. b Inhibitor FTI-277 as control. c Impact on 
GTPase Rap1A in cells (5 µM, 48 h). dAssay in MDAMB231 cells, repeated 3 times 
individual experiments) with 2 different time points of 48 hours and 72 hours. Data 
presented by one set of experiment with one time point (72 hours). +represents fold 












1 (DU40) 3.3 1.1b +++++ 23.0 ± 1.22 
2 2.4 ˃ 100 +++++ 7.6 ± 1.08 
3 11.6 ˃ 100 ++ 29.4 ± 1.01 
4 7.8 ˃ 100 +++ ˃ 50 
5 3.1 ˃ 100 +++++ 33.2 ± 1.29 
6 22.9 ˃ 100 + 15.4 ± 1.03 
7 31.9 ˃ 100 ++ ˃ 50 
8 26.3 ˃ 100 +++ 13.2 ± 1.06 
9 19.7 ˃ 100 ++ ˃ 50 
10 34.8 ˃ 100 + 14.8 ± 1.08 
11 9.9 ˃ 100 ++ ˃ 50 
12 ˃ 50 ˃ 100 - ˃ 50 
13 ˃ 50 ˃ 100 - ˃ 50 
14 ˃ 50 ˃ 100 - ˃ 50 
15 26.9 ˃ 100 - 34.9 ± 1.06 
16 19.0 ˃ 100 - 26.5 ± 1.10 
51 
 
3.2.2 Western blot analysis 
Rap1A is normally isoprenylated by GGTase-I and is used as an indicator for protein 
geranylgeranylation. In the Western blot analysis, the impairment of prenylation is noted 
by the use of anti-Rap1A antibody that selectively recognizes the unprenylated form of the 
Rap1A, a band indicating an alteration in Rap1A geranylgeranylation. This cellular assay 
was used to examine the capacity of the compounds to inhibit GGTase-I in an intact cell, 
namely the breast cancer cell line MDA-MB-231. ImageJ software was used to quantitate 
the Rap1A expression and normalized with internal control tubulin (Table-1).  In normal 
growing cells treated with the DMSO control (10 L of DMSO (0.5%)), all the Rap1A was 
geranylgeranylated and the lane was fairly blank.  When GGTase-I was inhibited by GGTI 
DU40 (control), the accumulation of unprenylated Rap1A was readily observed (Fig. 11). 
Compounds 2 and 5 have shown the highest level of Rap1A expression which is in line 
with their highest GGTase-I inhibitory activity. These data indicated the capacity of 2 and 
5 to inhibit prenylation of endogenous proteins. Moreover, compounds that showed similar 
GGTase-I inhibitory activity have shown almost similar alteration in Rap1A 
geranylgeranylation. For instance, compounds 4 (IC50 = 7.8 µM) and 11 (IC50 = 9.9 µM) 
have exhibited similar levels of Rap1A expression so was the case with compounds 6 (IC50 
= 22.9 µM) and 10 (IC50 = 34.8 µM). Likewise, compounds 12-14 that were inactive in the 
GGTase-I inhibition did not alter Rap1A geranylgeranylation. The lower cellular activities 





Figure 11: Inhibition of geranylgeranylation of Rap1A in MDA-MB-231 cells by 2-16. 
Western blots of Rap1A following 48 hours treatments with the indicated inhibitors at a 
concentration (5 µM). Tubulin was used as the loading control for the immunoblot and 
GGTI- DU40 as the positive control inhibitor. The anti-Rap1A antibody detects the 
unprenylated form of Rap1A, a band indicating a reduction in Rap1A geranylgeranylation. 
3.2.3 Cell proliferation assay 
To determine the in vitro dose-dependent cytotoxicity effect of compounds 2-16, the ability 
of 2-16 to inhibit growth of breast cancer cells MDA-MB-231 were assessed using the 
MTT assay (Fig. 12). This colorimetric assay is based on the ability of mitochondrial 
enzymes of live cells to reduce MTT to formazan salt. The cultured cells were treated with 
compounds at various concentration (2 - 32 μM) followed by the determination of cell 
growth by CellTiter 96® Aqueous one (Promega) cell proliferation assay solution after 48 
hours. The cytotoxic effects of the extracts were estimated in terms of growth inhibition 
percentage with reference to the control (DMSO treated cells) and expressed as IC50 values 
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(Table-3). Whereas compounds 12-14 were found to be inactive in both GGTase-I 
inhibition as well as MTT assay, the activities of compounds 6, 8, 15 and 16 were almost 
comparable i.e. showing moderate GGTase-I inhibition and cytotoxicity in MTT assay. In 
addition, 2 (IC50 = 7.6 µM) turned out to be the most active compound which has shown 
significantly higher activity compared to 1 (IC50 = 23.0 µM). There is a general, but not 
perfect, correlation with impact on Rap1A prenylation and IC50 in the MTT assay, both of 
which read out cellular activity. The GGTase IC50 may not correlate for reasons of cell 
permeability as noted above.  
 




3.3  Molecular docking studies 
In order to probe the possible binding mode of 2-16, compound 2 was docked into GGTase-
I binding pocket based on the co-crystal structure of GGTase-I complexed with a GGPP 
Analog and a KKKSKTKCVIL peptide (PDB ID: 1N4Q) using Glide (Glide, Schrodinger 
Inc.) [26]. The GGTase-I binding pocket is lined by mainly hydrophobic residues that bind 
the methyl‐5‐geranyl‐4‐methyl‐pent‐3‐enyl moiety. At the entrance of the binding pocket, 
the positively charged residues Arg172, Lys266, Arg263, and His219 bind to the phosphate 
group of the co‐ crystallized ligand (Fig. 13). 
 
Figure 13: Binding of the native ligand 
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Computationally removing the KKKSKTKCVIL peptide substrate from enzyme exposed 
a large volume of the active site, which in turn resulted in different docking poses of 2 
using the two scoring function of Glide, SP and XP [129,130]. Based on Figures 14a and 
14b, Thr45 and Arg173 serve as hydrogen bond donors for the primary amide oxygen and 
oxygen at C-5 of the pyrazole moiety, respectively. Similarly, Ser46 and Thr49 are 
hydrogen bond acceptors for the primary amide hydrogens of 2 (Fig. 14b). In addition, 2 
is engaged in π-π contacts through the 4-fluorophenyl (Fig. 14a) and 3,4-dichlorophenyl 
moieties (Fig. 14b) to the imidazole moiety of His121 and via pyridyl ring to the phenyl 
moiety of Tyr126 (Fig. 14b). However, when the KKKSKTKCVIL peptide was kept in the 
binding pocket, the obtained poses using the SP and XP scoring functions of Glide are very 
similar. The central pyrimidine phenyl diazole is kept inside the hydrophobic pocket, while 
the peptidic part orients itself towards the solvent and assumes different conformations 
between the SP and XP modes. By keeping the KKKSKTKCVIL peptide in the pocket, 
Glu 169 and Leu 511 acted as hydrogen bond acceptors for the primary amide hydrogens 
of 2 (Fig. 14c) and so was the case for Asp 269 (Fig. 14d). Additional H-bond interactions 
were evident between the nitrogen (N-2) of pyrazole moiety of 2 with Gln 212 (Fig. 14c & 
14d) as well as between the Arg 263 and Tyr 272 with the secondary and primary amide 
oxygens, respectively (Fig. 14d). Additional π-π contact of 2 was observed through the 3,4-
dichlorophenyl, pyridyl, pyrazole and 4-fluorophenyl moieties with Hie 219, Trp 272, Arg 




Figure 14: Molecular docking of 2 into GGTase-1 binding pocket without the   
KKKSKTKCVIL peptide. 
(a) Using the Glide SP mode and (b) using the Glide XP mode. Molecular Docking of 2 
into GGTase-1 binding pocket in presence of the KKKSKTKCVIL peptide (c) using the 













4.1 Instruments and chemicals 
General: Melting Points were determined on a Büchi apparatus (Büchi Labortechnik AG, 
Switzerland) and are uncorrected. Elemental analysis was carried out on a Perkin Elmer 
Elemental Analyzer Series 11 Model 2400 (PerkinElmer Inc. USA). IR spectra were 
recorded on a Perkin Elmer 16F PC FTIR spectrophotometer (PerkinElmer Inc. USA) and 
reported in wavenumber (cm-1). 1H and 13C NMR spectra were measured in CDCl3 and d6-
DMSO using TMS as internal standard on a JEOL JNM-LA 500 MHz spectrometer (JEOL 
USA Inc.). Chemical shifts were reported in ppm (δ) relative to tetramethyl silane (TMS) 
by using CDCl3, DMSO or d4-methanol as deuterated solvents. Multiplicities in signals of 
1H-NMR were recorded and reported as singlet (s), doublet (d), triplet (t), quartet (q) or 
multiplet (m) and coupling constant (J) were measured and reported in Hz.    
 
Analytical TLC was carried out on silica gel 60 F254 plates (E. Merck) for monitoring of 
reactions as well as qualitative determination of sample purity by analyzing the spots under 
spectroline UV lamp operating at short and long wavelength ranges. For UV insensitive 
samples the visualization was improved by using solution of phosphomolybdic acid (PMA) 
and iodine chamber. Column chromatography was carried out on silica gel (200-400 mesh, 
E. Merck) for purification of the products. 
 
Chemical were purchased from the most credible manufacturers like Sigma Aldrich, Fluka, 
Merck Chemicals, and BDH etc. and used without further purification unless otherwise 
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specified. All solvents used were of reagent or analytical grade and anhydrous solvents 
were used wherever necessary. Glassware was dried in an oven (Precision, Winchester, 
Virginia) at 120-140 oC for 3-4 hours and cooled in silica gel containing desiccators prior 
to use in case of moisture sensitive reactions. Similarly, reaction requiring inert conditions 
were performed under nitrogen or helium atmosphere. 
4.2 Synthesis of target compounds 2-5 
The synthesis of target compounds 2-5 was accomplished from intermediates 50-53 by the 
operations of mesylation that followed condensation of the resultant mesylates with sodium 
methanethiolate. The intermediates 50-53, in turn, were synthesized from the amidation 
reaction of amino acid derivatives 25-28 and the key intermediate 49. The detailed 
description about the syntheses procedures and spectroscopic analysis including 1H-NMR, 
13C-NMR, FTIR, elemental analysis, melting points and specific rotation (if necessary) for 
all the intermediates and final target compounds is given below;  
4.2.1 Synthesis of (S)-Methyl 2-amino-3-(4-fluorophenyl)propanoate 
hydrochloride (20) 
 
To a solution of L-4-fluorophenylalanine (3.0 g, 16.37 mmol) in anhydrous methanol (50 
mL), thionyl chloride (9 mL) was added dropwise in about 30 minutes at 0°C and the 
mixture was stirred overnight at room temperature. The solvent was removed under 
reduced pressure and the crude product was purified by recrystallization with diethyl ether 
to obtain the title compound 20 as a colorless solid in quantitative yield [116]. 1H NMR 
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(500 MHz, DMSO): δ 3.23-3.35 (dd, J=5.8, 7.5 Hz, 1H, CH-CH2), 3.42-3.45 (dd, J=5.8, 
6.7 Hz, 1H, CH-CH2), 3.74 (s, 3H, CH3), 4.33 (m, 1H, CH-CH2), 7.23 (d, J= 10.1 Hz, 2H, 
Ar-H), 7.35 (d, J = 6.1Hz, 2H, Ar-H). 13C-NMR (125.7 MHz, DMSO): δ 28.25 (CH-CH2), 
55.28 (CH-CH2), 57.48 (OCH3), 114.18 (Carom), 127.74 (Carom), 130.66 (Carom), 158.85 (F-
C), 158.88 (F-C), 175.10 (COOCH3). Anal. Calcd for C10H13ClFNO2 (233.06): C 51.40, H 
5.61, N 5.99; Found: C 50.80, H 6.01, N 5.89. 
 
4.2.2 Synthesis of (S)-methyl 2-amino-3-(pyridin-3-yl)propanoate 
hydrochloride (21) 
 
Following the procedure adopted for the synthesis of 20, the reaction of L-3-pyridylalanine 
with NH4OH yielded compound 21 as a light yellow solid (yield 95%) [117]. IR (neat): 
3472.3, 3173.6, 1743.9, 1615.0, 1556.1, 1470.0, 1374.7, 1289.5, 1219.5, 1069.1, 805.6, 
678.7 cm-1. 1H-NMR (500 MHz, CD3OD): δ 3.39-3.34 (dd, J=7.3, 6.7 Hz, 1H, CH-CH2), 
3.5-3.45 (dd, J=7.3, 9.5 Hz, 1H, CH-CH2), 3.72 (s; 3H, CH3), 4.49 (m; 1H, CH-CH2), 7.93 
(t; J= 7.3 Hz, 1H, Ar-H), 8.39 (d, J= 7.95 Hz, 1H, Ar-H), 8.58 (s, 1H, Ar-H),  8.80 (d, 
J=5.45 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, DMSO): δ 32.37 (CH-CH2), 52.35 (CH-
CH2), 53.10 (OCH3), 126.49 (Carom), 134.44 (Carom), 142.09 (Carom), 144.07 (Carom), 145.45 
(Carom), 168.85 (COOCH3). Anal. Calcd for C9H14Cl2N2O2 (252.04): C 42.70, H 5.57, N 
11.07; Found: C 41.60, H 5.25, N 12.17. 
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4.2.3 Synthesis of (S)-methyl 2-amino-3-(pyridin-4-yl)propanoate 
hydrochloride (22) 
 
Following the procedure adopted for the synthesis of 20, the reaction of L-4-pyridylalanine 
with NH4OH yielded compound 22 as a light yellow solid (yield 92%). IR (neat): 3510.0, 
3223.5, 1737.4, 1635.4, 1500.2, 1430.1, 1376.6, 1285.9, 1217.3, 1133.6, 970.4, 807.5, 
573.7 cm-1.  1H-NMR (500 MHz, CD3OD): δ  3.56-3.53 (dd, J=6.1, 7.95 Hz, 1H, CH-CH2), 
3.62-3.60 (dd, J=7.95, 4.6 Hz, 1H, CH-CH2), 3.81 (s; 3H, CH3), 4.65 (m, J= 7.0 Hz, 1H, 
CH-CH2), 8.13 (d, J= 6.1 Hz, 2H, Ar-H), 8.86 (d, J= 5.45 Hz, 2H, Ar-H). 
13C-NMR (125.7 
MHz, DMSO): δ 37.12 (CH-CH2), 53.49 (CH-CH2), 54.02 (OCH3), 129.68 (Carom), 142.81 
(Carom), 142.90 (Carom), 158.31 (Carom), 169.36 (COOCH3). Anal. Calcd for C9H14Cl2N2O2 
(252.04): C 42.70, H 5.57, N 11.07; Found: C 42.60, H 6.25, N 12.47. 
4.2.4 Synthesis of (S)-methyl 2-amino-3-(4-methoxyphenyl)propanoate 
hydrochloride (24) 
The synthesis of 24 was achieved by esterification of L-tyrosine to get 24a, which was 
condensed with di-tert-butyl dicarbonate (Boc anhydride) to produce intermediate 24b. 
The O-alkylation of 24b with iodomethane furnished 24c and the exposure of the latter to 





4.2.5 Synthesis of (S)-methyl 2-amino-3-(4-hydroxyphenyl)propanoate 
(24a) 
 
To a solution of L-Tyrosine (5.0 g, 47.5 mmol) in methanol (25 mL), thionyl chloride (10 
mL) was added at 0°C and the mixture was then stirred overnight at room temperature. 
After concentration under reduced pressure, the recrystallization of the crude product with 
diethyl ether gave the tittle compound 24a as a colorless solid (yield, 99%) [131]. IR (neat): 
3342.0, 2883.2, 1743.7, 1613.6, 1514.7, 1449.6, 1396.4, 1105.6, 1057.6, 839.9, 732.0 cm-
1. 1H-NMR (500 MHz, CD3OD): δ 3.20-3.10 (dd, J= 5.1, 6.5 Hz, 1H, CH-CH2), 3.37-3.25 
(dd, J=6.1, 7.95 Hz, 1H, CH-CH2), 3.82 (s, 3H, CH3), 4.28 (m, 1H, CH-CH2), 6.81 (d, J=8.5 
Hz, 2H, Ar-H), 7.10 (d, J= 8.5 Hz, 2H, Ar-H). 13C-NMR (125.7 MHz, DMSO): δ 36.7 
(CH-CH2), 53.7 (CH-CH2), 55.6 (0CH3), 117.0 (Carom), 131.7 (Carom), 125.8 (Carom), 158.4 
(Carom), 170.6 (C=O). Anal. Calcd for C10H14ClNO3 (231.07): C 51.84, H 6.09, N 6.05; 
Found: C 50.96, H 5.97, N 7.05. 
4.2.6 Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(4-
hydroxyphenyl)propanoate (24b) 
 
To a solution of mixture of 24a (2.50 g, 10.84 mmol) and K2CO3 (1.82 g, 21.68 mmol) in 
THF/methanol (50 ml/15 ml) was added di-tert-butyl dicarbonate (2.366 g, 10.84 mmol) 
dissolved in THF (20 ml). The solution was stirred for 22 h at room temperature and the 
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solvents were then removed in vacuo. The residue was dissolved in CH2Cl2, washed with 
water and the organic layer was dried over MgSO4. The filtrate was concentrated under 
reduced pressure. Recrystallization of the residue from CH2Cl2 yielded 24b as white 
crystalline solid (yield, 84%) [132]. IR (neat): 3389.7, 3002.6, 2978.3, 2952.0, 1717.2, 
1688.9, 1617.0, 1446.1, 1396.1, 1159.3, 994.0, 830.1 cm-1.  1H-NMR (500 MHz, CDCl3): 
δ 1.42 (s, 9H, (CH3)3), 2.98-2.95 (dd: J=7.05, 6.4 Hz, 1H, CH), 3.05-3.02 (dd, J=5.5, 6.4 
Hz, 1H, CH), 3.71 (s, 3H, CH3), 4.54 (m, 1H, CH-CH2), 5.01 (d, J= 9.45Hz, 1H, NH), 5.62 
(s: 1H, OH), 6.74 (d, J=7.65 Hz, 2H, Ar-H), 6.97 (d, J=8.25 Hz, 2H, Ar-H). 13C-NMR (500 
MHz, CDCl3): δ 28.5 ((CH3)3), 37.7 (CH-CH2), 52.4 (OCH3), 54.8 (CH-CH2), 80.4 
(OC(CH3)3), 115.7 (Carom), 127.7 (Carom), 130.5 (Carom), 155.3 (Carom), 155.5 (COOCH3), 
172.8 (CONH). Anal. calcd. for C15H21NO5 (295.14): C 61.00, H 7.17, N 4.74; Found C 
61.50, H 5.55, N 6.87. 
4.2.7 Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(4-
methoxyphenyl)propanoate (24c)  
 
To a solution of 24b (0.323g, 1.0936 mmol) in DMF (40 mL) was added NaHCO3 (0.226g, 
1.604 mmol) and after being stirred 10 minutes, MeI (0.1709 mL, 2.74 mmol) was added 
to the mixture dropwise. The reaction was stirred overnight at room temperature and then 
quenched with 1N HCl (40 mL). The mixture was transferred in a separating funnel and 
extracted with ethyl acetate (20 mL × 3) and the organic layer was washed with 1N HCl 
(20 mL x 3), H2O (20 mL) and brine (15 mL). The organic layer was dried over Na2SO4 
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and evaporated under reduced pressure to get the title compound 24c as pale yellow sticky 
solid (yield, 78%) [132]. IR (neat): 3445.9, 3347.9, 2978.7, 2929.8, 1717.7, 1513.9, 1513.9, 
1397.4, 1368.8, 1249.4, 1167.1, 1032.1, 829.7 cm-1. 1H-NMR (500 MHz, CDCl3):  δ 1.42 
(s, 9H, (CH3)3), 3.01-2.98 (dd, J=7.65, 6.45 Hz, 1H, CH-CH2), 3.07-3.03 (dd, J=6.75, 7.52 
Hz, 1H, CH-CH2), 3.71(s, 3H), 3.78 (s, 3H), 4.53 (m, 1H, CH-CH2), 4.97 (d: 1H, NH),  
6.83 (d: J=8.5 Hz, 2H, Ar-H), 7.04 (d, J=8.2 Hz, 2H, Ar-H). 13C-NMR (125.7 MHz, 
CDCl3): δ 28.20 ((CH3)3), 37.34 (CH-CH2), 52.05 (OCH3), 54.47 (CH-CH2), 55.10 
(OCH3), 79.75 (OC(CH3)3), 113.88 (Carom), 127.86 (Carom), 130.18 (Carom),155.03 (Carom), 
158.56 (Carom), 172.34 (COOCH3), 192.45 (COOC(CH3)3). Anal. Calcd for C16H23NO5 
(309.16): C 62.12, H 7.49, N 4.53; Found: C 61.42, H 6.49, N 5.20. 
4.2.8 Synthesis of (S)-methyl 2-amino-3-(4-methoxyphenyl)propanoate 
hydrochloride (24) 
 
Following the same procedure adopted for the synthesis of 20, the reaction of  (24c) with 
acetyl chloride in methanol yielded compound 24 as a white solid (yield, 85%) [120]. IR 
(neat): 3411.6, 3032.2, 2834.6, 1740.4, 1615.7, 1516.1, 1489.5, 1305.1, 1250.2, 1053.1, 
837.7 cm-1. 1H-NMR (500 MHz, CD3OD):  δ 3.01-2.98 (dd, J=6.8, 7.65 Hz, 1H, CH-CH2), 
3.07-3.03 (dd, J=6.75, 7.9 Hz, 1H, CH-CH2), 3.77 (s, 3H, CH3), 3.80 (s, 3H, CH3), 4.25 
(m, 1H, CH-CH2), 6.92 (d: J=8.5 Hz, 2H, Ar-H), 7.15 (d, J=8.5 Hz, 2H, Ar-H). 
13C-NMR 
(125.7 MHz, CDCl3): δ 36.59 (CH-CH2), 52.05 (OCH3), 54.47 (CH-CH2), 55.72 (OCH3), 
113.88 (Carom), 115.56 (Carom), 126.89 (Carom), 131.51 (Carom), 160.93 (Carom), 170.51 
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(COOCH3). Anal. Calcd for C11H16ClNO3 (245.08): C 53.77, H 6.56, N 5.70; Found: C 
52.87, H 6.96, N 6.30. 
4.2.9 Synthesis of (S)-2-amino-3-(4-fluorophenyl)propanamide (25) 
 
In a pressure vessel, a solution of compound 20 (0.50 g, 2.54 mmol) in NH4OH (2 mL) 
was heated overnight at 100 oC. After cooling to room temperature, the reaction was added 
CH2Cl2 (10 mL) and the organic layer was separated and dried over Na2SO4 and evaporated 
to get the title compound 25 as a light yellow solid (yield 95%) [116]. M. p. 153-154 oC. 
IR (neat): 3377, 3329, 2958, 2926, 2834, 1667, 1613, 1512, 1448, 1299, 1249, 1035 cm-1. 
1H-NMR (500 MHz, CD3OD): δ 3.04 (dd, J = 7.65, 13.9 Hz, 1H, CH2CH), 3.20 (dd, J = 
5.8, 13.9 Hz, 1H, CH2CH), 4.06 (m, 1H, CH2CH), 7.08 (m, 2H, 3'-H, 5'-H), 7.31 (m, 2H, 
2'-H, 6'-H). 13C-NMR (125.7 MHz, CD3OD): δ 37.82 (CH2CH), 55.60 (CH2CH), 116.76 
(d, J = 21.8 Hz, C-3', C-5'), 132.40 (d, J = 8.3 Hz, C-2', C-6'), 134.40 (C-1') 163.70 (d, J = 
247.0 Hz, C-4'), 171.82 (C=O). Anal. Calcd for C9H11FN2O (198.19): C 59.33 H 6.09, N 
15.38. Found: C 59.29, H 6.13, N 15.31. 
4.2.10 Synthesis of (S)-2-amino-3-(pyridin-3-yl)propanamide (26) 
 
Following the same procedure adopted for the synthesis of 25, the reaction of 21 with 




IR (neat): 3366, 2977, 2936, 1703, 1519, 1429, 1346, 1168, 1036 cm-1. 1H-NMR (500 
MHz, CD3OD): δ 2.88 (dd, J = 7.3, 13.7 Hz, 1H, CH2CH), 3.04 (dd, J = 6.4, 13.7 Hz, 1H, 
CH2CH), 3.62 (t, J = 7.0 Hz, 1H, CH2CH), 7.37 (m, 1H, 5'-H), 7.75 (m, 1H, 6'-H), 8.40 (d, 
J = 6.5 Hz, 1H, 4'-H), 8.42 (d, J = 1.3 Hz, 1H, 2'-H). 13C-NMR (125.7 MHz, CD3OD): δ 
34.85 (CH2CH), 54.48 (CH2CH), 125.22, 131.34, 139.39, 148.59, 149.70 (all Carom), 
172.23 (C=O). Anal. Calcd for C8H11N3O (181.19): C 58.17, H 6.71, N 25.44. Found: C 
58.13, H 6.76, N 25.37. 
4.2.11 Synthesis of (S)-2-amino-3-(pyridin-4-yl)propanamide (27) 
 
Following the same procedure adopted for the synthesis of 25, the reaction of compound 
22 with NH4OH gave compound 27 as a light yellow solid (yield 85%). M. p. 158-159 
oC. 
IR (neat): 3364, 3250, 3035, 2939, 1695, 1607, 1539, 1420, 1398, 1038 cm-1. 1H-NMR 
(500 MHz, CD3OD): δ 3.05 (dd, J = 7.9, 14.0 Hz, 1H, CH2CH), 3.22 (dd, J = 5.4, 14.0 Hz, 
1H, CH2CH), 4.02 (m, 1H, CH2CH), 7.38 (d, J = 6.1 Hz, 2H, 2'-H, 6'-H), 8.50 (d, J = 6.1 
Hz, 2H, 3'-H, 5'-H). 13C-NMR (125.7 MHz, CD3OD): δ 37.50 (CH2CH), 56.48 (CH2CH), 
126.53 (C-2', C-6'), 146.97 (C-1'), 150.47 (C-3', C-5'), 172.60 (C=O). Anal. Calcd for 







4.2.12 Synthsis of (S)-2-amino-3-(4-methoxyphenyl)propanamide (28)  
 
Following the same procedure adopted for the synthesis of 25, the reaction of compound 
24 with NH4OH gave the title compound 28 [120] as a light yellow solid (yield 94%). M. 
p. 177-178 oC. IR (neat): 3376, 3056, 2958, 1667, 1613, 1511, 1449, 1299, 1250, 1035 cm-
1. 1H-NMR (500 MHz, CD3OD): δ 2.75 (dd, J = 7.6, 13.9 Hz, 1H, CH2), 2.91 (dd, J = 6.1, 
13.9 Hz, 1H, CH2), 3.53 (m, 1H, CH), 3.75 (s, 3H, OCH3), 6.85 (d, J = 8.5 Hz, 2H, 3'-H, 
5'-H), 7.15 (d, J = 8.3 Hz, 2H, 2'-H, 6'-H). 13C NMR (125.7 MHz, CD3OD): δ 41.42 
(CH2CH), 55.65 (OCH3), 57.37 (CH2CH), 114.17 (C-3', C-5'), 130.51 (C-1'), 131.41 (C-2', 
C-6'), 160.12 (C-4'), 179.19 (C=O). Anal. Calcd for C10H14N2O2 (210.23): C 61.84, H 7.27, 
N 14.42. Found: C 61.79, H 7.33, N, 14.35. 
4.2.13 Synthesis of 3-nicotinoyldihydrofuran-2(3H)-one (46) 
 
A solution of NaOEt (8.16g, 120 mmol) in EtOH (38.8), making a concentration of 21% 
w/v, was added to a dry flask under N2. The mixture was cooled to 0
oC followed by the 
addition of ethylnicotinate (16.4 mL, 120 mmol) in one portion. ϒ-Butyrolactone (8 mL, 
120 mmol) was then added drop wise to mixture in 1 hr and the reaction was stirred first at 
0oC for 1 h followed by heating to 65 0C overnight. The ethanol was removed in vacuo and 
the residue was diluted with H2O (50 mL) and the unreacted materials were removed by 
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extraction with diethyl ether. The pH of aqueous phase was adjusted to 4-5 with 3N HCl 
and then extracted with CH2Cl2 (20 mL x 3). After washing with water and brine, the 
organic layer was dried over Na2SO4 and evaporated to yield 46 as a brown oil (Yield 
73%). IR (neat): 3411.2, 3058.01, 2918.1, 29.22.6, 1759.3, 1689.5, 1586.9, 1377.1, 1346.9, 
1021.9 cm-1. 1H-NMR (500 MHz, CDCl3):  2.52 (m,1H), 2.92 (m, 0.98H), 3.22 (t, 
J=7.5Hz, 0.35H), 4.5-4.3 (m, 3.34H), 7.42-7.41 (dd, J= 4.8 Hz, 1H), 8.32-8.30 (d, J= 3.9 
Hz; 1H), 8.7710-8.7582 (dd, J=1.5 Hz, 1H), 9.2 (d, J=2.15 Hz;1H). 13C-NMR (500 MHz, 
CDCl3): δ 22.07, 25.11, 48.41, 67.77, 68.47, 123.41, 123.75, 137.14, 137.39, 150.30, 
150.44, 152.71, 153.68, 177.77, 191.9. Anal. Calcd for C10H9NO3 (191.06): C 62.82, H 
4.74, N 7.33; Found: C 61.70, H 4.67, N 7.44. 
4.2.14 Synthesis of 2-(1-(3,4-Dichlorophenyl)-5-hydroxy-3-(pyridin-3-yl)-
1H-pyrazol-4-yl)ethyl acetate (47) 
 
A slightly modified procedure was followed [122]. To the solution of -ketobutyrolactone 
46 (4.78 g, 25.03 mmol) in acetic acid (20 mL) was added 3,4-dichlorophenylhydrazine 
hydrochloride (5.86 g, 27.5 mmol) in one portion. The mixture was heated at reflux 
overnight and then cooled to room temperature. The mixture was diluted with H2O (20 mL) 
and then extracted with EtOAc (2 x 30 mL). The combined organic layers was washed with 
saturated aqueous solution of NaHCO3 (2 x 15 mL), dried over Na2SO4 and evaporated 
under reduced pressure. Column chromatography of the light oily material eluting with 
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EtOAc-hexane (1:1) afforded the title compound 47 as a yellow solid (8.22 g, 84%). M. p. 
176-177 oC. IR (neat): 3426, 3099, 3076, 2993, 2984, 1725, 1589, 1475, 1409, 1250, 1025 
cm-1. 1H-NMR (500 MHz, d6-DMSO): δ 1.78 (s, 3H, COCH3), 2.84 (t, J = 6.4 Hz, 2H, 
ArCH2), 4.03 (t, J = 6.5 Hz, 2H, OCH2), 7.49 (dd, J = 2.1, 8.7 Hz, 1H, Ar-H), 7.73 (d, J = 
8.8 Hz, 1H, Ar-H), 7.84 (dd, J = 2.1, 6.8 Hz, 1H, Ar-H), 8.06 (m, 2H, Ar-H), 8.58 (d, J = 
1.8 Hz, 1H, Ar-H), 8.86 (s, 1H, Ar-H). 13C-NMR (125.7 MHz, d6-DMSO): δ 20.55 
(COCH3), 21.63 (Ar-CH2), 63.13 (OCH2), 120.65, 122.04, 123.84, 127.87, 131.09, 131.49, 
135.01, 138.18, 147.79, 148.01, 149.17 (all Carom), 170.31 (C=O). Anal. Calcd for 
C18H15Cl2N3O3 (391.05): C 55.12, H 3.85, N 10.71; Found: C 55.08, H 3.89, N 10.65. 
4.2.15 Synthesis of Ethyl 4-((4-(2-acetoxyethyl)-1-(3,4-dichlorophenyl)-3-
(pyridin-3-yl)-1H-pyrazol-5-yl)oxy)buta-noate (48) 
 
To a solution of 47 (2.0 g, 5.10 mmol) in anhydrous DMF (20 mL) was added K2CO3 (1.06 
g, 7.65 mmol) followed by the addition of ethyl 4-bromobutanoate (0.88 mL, 6.12 mmol) 
and the mixture was stirred for 4 hours at room temperature until the completion of the 
reaction (TLC analysis). The reaction was diluted with EtOAc (30 mL) and then washed 
successively with 1M aqueous HCl (10 mL), H2O (10 mL) and brine (10 mL). The organic 
layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. Column 
chromatography of the light orange oily material, eluting with EtOAc-hexane (8:2) 
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afforded the title compound 48 as a yellow thick oil (1.42 g, 54%). IR (neat): 3034, 2954, 
1740, 1592, 1484, 1415, 1366, 1230, 1029 cm-1. 1H-NMR (500 MHz, CD3OD): δ 1.26 (t, 
J = 7.0 Hz, 2H, CH3CH2O), 1.96 (s, 3H, COCH3), 2.07 (quint, 2H, J = 6.7 Hz, 2H, -
CH2CH2CH2-), 2.48 (t, J = 7.3 Hz, 2H, CH2CO2Et), 2.96 (t, J = 7.0 Hz, 2H, ArCH2), 4.04 
(t, J = 6.4 Hz, 2H, OCH2), 4.14 (q, J = 7.0 Hz, 2H, CH3CH2O), 4.19 (t, J = 7.0 Hz, 2H, 
OCH2), 7.57 (d, J = 8.8 Hz, 1H, Ar-H), 7.61-7.66 (m, 2H, Ar-H), 7.93 (d, J = 2.4 Hz, 1H, 
Ar-H), 8.36 (d, J = 7.9 Hz, 1H, Ar-H), 8.67 (d, J = 4.5 Hz, 1H, Ar-H), 9.06 (br. s, 1H, Ar-
H). 13C-NMR (125.7 MHz, CD3OD): δ 14.16 (CH3CH2O), 20.08 (COCH3), 22.41 (Ar-
CH2), 25.03 (-CH2CH2CH2-), 30.17 (CH2CO2Et), 60.68 (CH3CH2O), 63.30 (OCH2), 74.67 
(OCH2), 103.13, 121.05, 123.83, 124.79, 130.65, 130.89, 131.25, 133.32, 137.30, 137.98, 
144.95, 145.36, 146.39, 152.43 (all Carom), 170.83 (C=O), 172.44 (C=O). Anal. Calcd for 
C24H25Cl2N3O5 (505.12): C 56.93, H 4.98, N 8.30; Found: C 56.85, H 5.03, N 8.25. 
4.2.16 Synthesis of 4-((1-(3,4-Dichlorophenyl)-4-(2-hydroxyethyl)-3-
(pyridin-3-yl)-1H-pyrazol-5-yl)oxy)butanoic acid (49) 
 
To a solution of 48 (1.64 g, 3.24 mmol) in a mixture of MeOH-H2O-THF (25 mL, 1:1:3) 
was added LiOH.H2O (0.68 g, 16.2 mmol) and the mixture was stirred for 4 hours at room 
temperature until the completion of the reaction (TLC analysis). The volatiles were 
evaporated under reduced pressure to get the title compound 49 as a white crystalline solid 
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(1.10 g, 78%). M. p. 119-120 oC. IR (neat): 3388, 2954, 2922, 1677, 1594, 1489, 1452, 
1368, 1146, 1024 cm-1. 1H-NMR (500 MHz, CD3OD):  2.00 (quint, J = 7.3 Hz, 2H, -
CH2CH2CH2-), 2.28 (t, J = 7.3 Hz, 2H, CH2CO2H), 2.86 (t, J = 7.3 Hz, 2H, ArCH2), 3.66 
(t, J = 7.0 Hz, 2H, OCH2), 4.08 (t, J = 6.7 Hz, 2H, OCH2), 7.53 (dd, J = 4.8, 7.9 Hz, 1H, 
Ar-H), 7.68 (d, J = 8.5 Hz, 1H, Ar-H), 7.75 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 7.97 (d, J = 
2.4 Hz, 1H, Ar-H), 8.18 (m, 1H, Ar-H), 8.55 (dd, J = 1.5, 4.8 Hz, 1H, Ar-H), 8.89 (d, J = 
1.4 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CD3OD):  26.36 (ArCH2), 27.22 
(CH2CH2CH2), 31.22 (CH2CO2H), 62.19 (OCH2), 75.86 (OCH2), 105.20, 123.06, 125.26, 
131.71, 131.91, 132.26, 134.01, 137.33, 139.17, 149.08, 149.55, 153.89 (all Carom), 176.75 
(C=O). Anal. Calcd for C20H19Cl2N3O4 (435.08): C 55.06, H 4.39, N 9.63; Found: C 55.0, 
H 4.45, N 9.55. 




To a solution of mixture of compound 25 (0.089 g, 0.49 mmol) and 49 (0.32 g, 0.73 mmol) 
in anhydrous CH2Cl2 (15 mL) was sequentially added hydroxybenzotriazole (0.17 g, 1.1 
mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.28 g, 1.46 
mmol) and Et3N (0.51 mL, 3.65 mmol) and the reaction was stirred overnight at room 
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temperature. The mixture was diluted with ethyl acetate (30 mL) and washed with H2O (10 
mL) and brine (10 mL). The organic layer was dried over Na2SO4 and evaporated under 
reduced pressure. Column chromatography of thick oily material, eluting with the EtOAc-
hexane (8:2) gave the desired product 50 as a white solid (yield 68%). M. p. 182-183 oC. 
IR (neat): 3356, 3292, 3051, 2956, 1632, 1593, 1481, 1418, 1222, 1028 cm-1. 1H-NMR 
(500 MHz, CD3OD): δ 1.92 (t, J = 6.7 Hz, 2H, COCH2), 2.30 (pent, 2H, CH2CH2CH2), 
2.83 (m, 3H, ArCH2, CH2CH), 3.12 (dd, J = 4.9, 11.6 Hz, 1H, CH2CH), 3.66 (t, J = 7.0 Hz, 
2H, OCH2), 3.96 (t, J = 6.7 Hz, 2H, OCH2), 4.58 (m, 1H, CH2CH), 6.93 (m, 2H, Ar-H), 
7.21 (m, 2H, Ar-H), 7.53 (dd, J = 2.4, 8.1 Hz, 1H, Ar-H), 7.65-7.71 (m, 2H, Ar-H), 7.93 
(d, J = 2.1 Hz, 1H, Ar-H), 8.17 (dd, J = 2.3, 8.1 Hz, 1H, Ar-H), 8.55 (d, J = 8.3 Hz, 1H, 
Ar-H), 8.88 (d, J = 2.3 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CD3OD): δ 26.81 (ArCH2), 
27.21 (CH2CH2CH2), 32.77 (COCH2), 38.26 (CH2CH), 55.52 (OCH2), 62.21 (CH2CH), 
75.81 (OCH2), 105.19, 115.98 (d, J = 21.8 Hz), 122.94, 125.13, 125.27, 131.70, 131.81, 
131.95, 132.27, 133.97, 134.57, 137.32, 139.18, 149.05, 149.56, 153.81, 163.56 (d, J = 
248.0 Hz) (all Carom), 174.65 (C=O), 176.05 (C=O). Anal. Calcd for C29H28Cl2FN5O4 
(600.47): C 58.01, H 4.70, N 11.66; Found: C 57.94, H 4.76, N 11.60. 






Following the procedure adopted for the synthesis of 50, the reaction of 49 with 26 gave 
compound 51 as a yellowish gum (yield 62%). IR (neat): 3417, 2925, 1668, 1593, 1482, 
1368, 1024 cm-1. 1H-NMR (500 MHz, CD3OD): δ 1.90 (t, J = 6.7 Hz, 2H, COCH2), 2.31 
(pent, 2H, CH2CH2CH2), 2.83 (t, J = 6.7 Hz, 2H, ArCH2), 2.89 (dd, J = 9.1, 13.7 Hz, 1H, 
CH2CH), 3.19 (dd, J = 5.5, 13.7 Hz, 1H, CH2CH), 3.65 (t, J = 7 Hz, 2H, OCH2), 3.95 (t, J 
= 6.7 Hz, 2H, OCH2), 4.60 (m, 1H, CH2CH), 7.31 (dd, J = 4.8, 8.5 Hz, 1H, Ar-H), 7.53 
(dd, J = 4.9, 8.2 Hz, 1H, Ar-H), 7.67 (d, J = 8.7 Hz, 1H, Ar-H), 7.70 (dd, J = 2.45 Hz, 1H, 
Ar-H), 7.73 (m, 1H, Ar-H), 7.94 (d, J = 2.4 Hz, 1H, Ar-H), 8.20 (dd, J = 2.15, 8.0 Hz, 1H, 
Ar-H), 8.33 (dd, J = 1.5, 4.9 Hz, 1H, Ar-H), 8.41 (d, J = 1.5 Hz, 1H, Ar-H), 8.56 (dd, J = 
1.5, 4.9 Hz, 1H, Ar-H), 8.89 (d, J = 1.5 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CD3OD): 
δ 26.79 (ArCH2), 27.23 (CH2CH2CH2), 32.73 (COCH2), 36.23 (CH2CH), 54.89 (OCH2), 
62.19 (CH2CH), 75.84 (OCH2), 105.25, 122.92, 125.08, 125.11, 125.29, 131.68, 131.80, 
132.28, 133.97, 135.29, 137.32, 139.06, 139.17, 148.34, 149.03, 149.47, 149.57, 150.79, 
153.82 (all Carom), 174.67 (C=O), 175.51 (C=O). Anal. Calcd for C28H28Cl2N6O4 (543.47): 








Following the procedure adopted for the synthesis of 50, the reaction of 49 with 27 gave 
compound 52 as a white solid (yield 60%). M. p. 159-160 oC. IR (neat): 3402, 2924, 1689, 
1592, 1482, 1367, 1134, 1029 cm-1. 1H-NMR (500 MHz, CD3OD): δ 1.91 (t, J = 6.7 Hz, 
2H, COCH2), 2.32 (pent, 2H, CH2CH2CH2), 2.83 (t, J = 6.7 Hz, 2H, ArCH2), 2.91 (dd, J = 
9.7, 13.7 Hz, 1H, CH2CH), 3.20 (dd, J = 5.5, 13.7 Hz, 1H, CH2CH), 3.64 (t, J = 7 Hz, 2H, 
OCH2), 3.97 (t, J = 6.4 Hz, 2H, OCH2), 4.71 (m, 1H, CH2CH), 7.32 (d, J = 6.1 Hz, 2H, Ar-
H), 7.54 (m, 1H, Ar-H), 7.67 (d, J = 8.8 Hz, 1H, Ar-H), 7.71 (d, J = 8.8 Hz, 1H, Ar-H), 
7.94 (d, J = 2.4 Hz, 1H, Ar-H), 8.19 (d, J = 8.5 Hz, 1H, Ar-H), 8.40 (dd, J = 1.5, 4.9 Hz, 
1H, Ar-H), 8.56 (dd, J = 1.7, 4.9 Hz, 1H, Ar-H), 8.89 (d, J =1.5 Hz, 1H, Ar-H). 13C-NMR 
(125.7 MHz, CD3OD): δ 26.81 (ArCH2), 27.23 (CH2CH2CH2), 32.74 (COCH2), 38.34 
(CH2CH), 54.37 (OCH2), 62.21 (CH2CH), 75.86 (OCH2), 105.22, 125.96, 125.14, 125.29, 
126.34, 131.70, 131.81, 132.27, 133.97, 137.32, 139.18, 149.04, 149.49, 149.57, 149.92, 
153.82 (all Carom), 174.74 (C=O), 175.43 (C=O). Anal. Calcd for C28H28Cl2N6O4 (583.47): 
C 57.64, H 4.84, N 14.40; Found: C 57.56, H 4.88, N 14.33. 
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Following the procedure adopted for the synthesis of 50, the reaction of 49 with 28 gave 
compound 53 as a white solid (yield 66%). M. p. 175-176 oC. IR (neat): 3350, 3274, 3189, 
2925, 1676, 1641, 1593, 1482, 1248, 1049 cm-1. 1H NMR (500 MHz, CD3OD): δ 1.91 (t, J 
= 6.7 Hz, 2H, COCH2), 2.30 (pent, 2H, CH2CH2CH2), 2.75 (dd, J = 9.1, 13.7 Hz, 1H, 
CH2CH), 2.82 (t, J = 6.7 Hz, 2H, ArCH2), 3.06 (dd, J = 5.5, 13.7 Hz, 1H, CH2CH), 3.64 (t, 
J = 7.3 Hz, 2H, OCH2), 3.97 (t, J = 7.0 Hz, 2H, OCH2), 4.58 (m, 1H, CH2CH), 6.76 (d, J 
= 8.5 Hz, 2H, Ar-H), 7.14 (d, J = 8.5 Hz, 2H, Ar-H), 7.53 (m, 1H, Ar-H), 7.65 (d, J = 8.8 
Hz, 1H, Ar-H), 7.69 (dd, J = 2.1, 8.5 Hz, 1H, Ar-H), 7.94 (d, J = 2.1 Hz, 1H, Ar-H), 8.56 
(dd, J = 1.7, 4.9 Hz, 1H, Ar-H), 8.89 (d, J =1.5 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, 
CDCl3): δ 26.83 (ArCH2), 27.25 (CH2CH2CH2), 32.70 (COCH2), 38.30 (CH2CH), 54.39 
(OCH2), 62.20 (CH2CH), 75.82 (OCH2), 107.12, 115.22, 115.75, 122.39, 124.92, 125.07, 
129.47, 131.24, 131.26, 131.65, 132.27, 134.58, 136.36, 139.09, 149.31, 149.85, 150.70, 
153.44, 159.10 (all Carom), 172.80 (C=O), 174.30 (C=O). Anal. Calcd for C30H31Cl2N5O5 
(612.50): C 58.83, H 5.10, N 11.43; Found: C 58.77, H 5.16, N 11.35. 
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To a solution of compound 50 (0.15 g, 0.25 mmol) in THF (5 mL) at 0 oC was added Et3N 
(0.1 mL, 0.75 mmol) and after being stirred for 10 minutes, a solution of MsCl (0.03 mL, 
0.37 mmol) in THF (1 mL) was added dropwise. The reaction mixture was stirred for 2 
hours and then diluted with ethyl acetate (15 mL) and successively washed with H2O (5 
mL) and brine (2 x 5 mL). The organic layer was dried over Na2SO4 and evaporated under 
reduced pressure to get the mesylated product as light yellow thick oil, which was dissolved 
in DMF (7 mL) followed by the addition of sodium methane thiolate (0.04 g, 0.5 mmol) at 
0 oC. The stirring was continued for 2 hours until the completion of reaction (TLC analysis) 
and the mixture was then diluted with ethyl acetate (15 mL) and successively washed with 
H2O (5 mL) and brine (2 x 5 mL). The organic layer was dried over Na2SO4 and evaporated 
under reduced pressure. Column chromatography of the light yellow oily material, eluting 
with EtOAc-hexane (8:2) gave the title compound 2 as a colorless solid (yield 85%). M. p. 
140-141 oC. −[𝛼]D
20= –29.15 (c = 0.0029, EtOH). IR (neat): 3398, 3309, 3205, 3072, 2919, 
1661, 1592, 1482, 1366, 1221, 1025 cm-1. 1H-NMR (500 MHz, CDCl3): δ 2.03-2.08 (m, 
5H, SCH3, COCH2), 2.36 (pent, 2H, CH2CH2CH2), 2.63 (t, J = 7.6 Hz, 2H, SCH2), 2.87 (t, 
J = 7.5 Hz, 2H, ArCH2), 3.03 (m, 2H, CH2CH), 3.99 (t, J = 7.1 Hz, 2H, OCH2), 4.62 (m, 
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1H, CH2CH), 6.25 (d, J = 7.3 Hz, 1H, NH), 6.97 (m, 2H, Ar-H), 7.21 (m, 2H, Ar-H), 7.39 
(m, 1H, Ar-H), 7.54 (d, J = 8.8 Hz, 1H, Ar-H), 7.65 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 7.93 
(d, J = 2.4 Hz, 1H, Ar-H), 8.00 (dd, J = 2.3, 8.5 Hz, 1H, Ar-H), 8.63 (d, J = 2.4 Hz, 1H, 
Ar-H), 8.89 (s, 1H, Ar-H). 13C-NMR (125.7 MHz, CDCl3): δ 15.62 (SCH3), 23.12 (Ar-
CH2), 25.37 (CH2CH2CH2), 32.11 (COCH2), 34.04 (SCH2), 37.58 (CH2CH), 54.12 
(CH2CH), 74.57 (OCH2), 105.74, 115.65 (d, J = 21.8 Hz), 115.73, 121.01, 123.63, 130.72, 
130.73, 130.76, 130.79, 130.86, 131.98, 132.0 (d, J = 3.1 Hz), 133.09, 134.95, 137.65, 
148.54, 149.35, 163.59 (d, J = 247 Hz) (all Carom), 171.42 (C=O), 172.36 (C=O). Anal. 
Calcd for C30H30Cl2FN5O3S (630.56): C 57.14, H 4.80, N 11.11; Found C 57.08, H 4.87, 
N 11.04. 




Following the procedure adopted for the synthesis of 2, acylation of 51 with MsCl followed 
by condensing the resultant mesylate with sodium methane thiolate yielded compound 3 as 
an off white gum (yield 75%). −[𝛼]D
20= –44.1 (c = 0.0015, EtOH).  IR (neat): 3393, 3186, 
3047, 2958, 2857, 1738, 1673, 1592, 1481, 1366, 1026 cm-1. 1H-NMR (500 MHz, CDCl3): 
δ 1.92 (t, J = 6.7 Hz, 2H, COCH2), 1.99 (s, 3H, SCH3), 2.32 (pent, 2H, CH2CH2CH2), 2.55 
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(t, J = 7.6 Hz, 2H, SCH2), 2.81 (t, J = 6.7 Hz, 2H, ArCH2), 3.12 (dd, J = 7.6, 14.3 Hz, 1H, 
CH2CH), 3.24 (dd, J = 5.8, 14.3 Hz, 1H, CH2CH), 3.91 (t, J = 6.1 Hz, 2H, OCH2), 4.82 (m, 
1H, CH2CH), 7.12 (d, J = 8.1 Hz, 1H, NH), 7.36 (m, 1H, Ar-H), 7.44-7.49 (m, 2H, Ar-H), 
7.58 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 7.85 (d, J = 2.4 Hz, 1H, Ar-H), 7.88 (m, 1H, Ar-H), 
7.99 (m, 1H, Ar-H), 8.45 (d, J = 5.2 Hz, 1H, Ar-H), 8.56 (d, J = 5.2 Hz, 1H, Ar-H), 8.76 
(d, J = 1.7 Hz, 1H, Ar-H), 8.87 (d, J = 1.7 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CDCl3): 
δ 15.64 (SCH3), 23.15 (Ar-CH2), 25.38 (CH2CH2CH2), 32.10 (COCH2), 34.03 (SCH2), 
35.43 (CH2CH), 53.68 (CH2CH), 74.57 (OCH2), 105.77, 121.10, 123.64, 123.60, 129.60, 
130.72, 130.88, 132.04, 133.10, 134.96, 136.92, 137.66, 147.92, 148.51, 149.34, 150.40, 
151.79 (all Carom), 171.60 (C=O), 172.07 (C=O). Anal. Calcd for C29H30Cl2N6O3S 
(613.56): C 56.77, H 4.93, N 13.70; Found: C 56.72, H 4.98, N 13.63. 




Following the procedure adopted for the synthesis of 2, acylation of 52 with MsCl followed 
by condensing the resultant mesylate with sodium methane thiolate yielded compound 4 as 
a white solid (yield 67%). M. p. 183-184 oC. −[𝛼]D
20= –96.60 (c = 0.0012, EtOH). IR (neat): 
3342, 3279, 3050, 2935, 1681, 1645, 1480, 1420, 1131, 1024 cm-1. 1H-NMR (500 MHz, 
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CD3OD): δ 2.0 (t, J = 6.7 Hz, 2H, COCH2), 2.07 (s, 3H, SCH3), 2.38 (pent, 2H, 
CH2CH2CH2), 2.63 (t, J = 7.3 Hz, 2H, SCH2), 2.87 (t, J = 6.7 Hz, 2H, ArCH2), 3.10 (dd, J 
= 9.3, 13.9 Hz, 1H, CH2CH), 3.18 (dd, J = 5.6, 13.9 Hz, 1H, CH2CH), 3.99 (t, J = 6.7 Hz, 
2H, OCH2), 4.78 (m, 1H, CH2CH), 7.30 (d, J = 6.8 Hz, 2H, Ar-H), 7.41 (m, 1H, Ar-H), 
7.55 (d, J = 8.5 Hz, 1H, Ar-H), 7.65 (dd, J = 2.7, 8.5 Hz, 1H, Ar-H), 7.93 (d, J = 2.7 Hz, 
1H, Ar-H), 8.03 (m, 1H, Ar-H), 8.53 (d, J = 6.9 Hz, 2H, Ar-H), 8.62 (m, 1H, Ar-H), 8.91 
(d, J =1.7 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CDCl3): δ 15.67 (SCH3), 23.17 (Ar-CH2), 
25.39 (CH2CH2CH2), 32.08 (COCH2), 34.05 (SCH2), 37.67 (CH2CH), 53.12 (CH2CH), 
74.61 (OCH2), 105.80, 121.07, 123.66, 123.72, 125.21, 130.92, 135.29, 148.19, 148.29, 
148.97, 153.80 (all Carom), 171.78 (C=O), 172.07 (C=O). Anal. Calcd for C29H30Cl2N6O3S 
(613.56): C 56.77, H 4.93, N 13.70; Found: C 56.73, H 4.98, N 13.64. 




Following the procedure adopted for the synthesis of 2, acylation of 53 with MsCl followed 
by condensing the resultant mesylate with sodium methane thiolate yielded compound 5 as 
a colorless solid (yield 70%). M. p. 154-155 oC. −[𝛼]D
20= –79.13 (c = 0.0007, EtOH). IR 
(neat): 3341, 3300, 3040, 2922, 1677, 1592, 1512, 1481, 1245, 1028 cm-1. 1H-NMR (500 
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MHz, CD3OD): δ 2.05 (t, J = 7.6 Hz, 2H, COCH2), 2.07 (s, 3H, SCH3), 2.36 (pent, 2H, 
CH2CH2CH2), 2.63 (t, J = 7.3 Hz, 2H, SCH2), 2.87 (t, J = 7.6 Hz, 2H, ArCH2), 2.99 (dd, J 
= 6.1, 13.7 Hz, 1H, CH2CH), 3.03 (dd, J = 4.9, 13.7 Hz, 1H, CH2CH), 3.77 (s, 3H, OCH3), 
3.99 (t, J = 6.7 Hz, 2H, OCH2), 4.61 (m, 1H, CH2CH), 6.82 (d, J = 8.2 Hz, 2H, Ar-H), 7.14 
(d, J = 8.2 Hz, 2H, Ar-H), 7.38 (m, 1H, Ar-H), 7.52 (d, J = 8.5 Hz, 1H, Ar-H), 7.64 (dd, J 
= 2.1, 8.5 Hz, 1H, Ar-H), 7.92 (d, J = 2.1 Hz, 1H, Ar-H), 8.00 (m, 1H, Ar-H), 8.62 (dd, J 
= 1.6, 6.1 Hz, 1H, Ar-H), 8.90 (d, J = 1.5 Hz, 1H, Ar-H). 13C-NMR (125.7 MHz, CDCl3): 
δ 17.04 (SCH3), 24.54 (Ar-CH2), 26.84 (CH2CH2CH2), 32.47 (COCH2), 34.06 (SCH2), 
35.43 (CH2CH), 56.64 (OCH3), 57.82 (CH2CH), 76.06 (OCH2), 107.17, 115.42, 115.55, 
122.39, 124.99, 125.04, 129.67, 131.04, 131.21, 131.69, 132.27, 134.52, 136.37, 139.06, 
149.33, 149.95, 150.75, 153.24, 160.12 (all Carom), 172.86 (C=O), 174.33 (C=O). Anal. 





4.3 Synthesis of target compounds 6-16 
Similarly the synthesis of 6-16 target compounds need the amino acid derivatives 33-40, 
42-44 and main intermediate 58 for amidation reaction. The detailed description 
comprising of procedures, 1H-NMR, 13C-NMR, FTIR, elemental analysis, melting points 
and specific rotation (if necessary) for all the step wise synthesis of intermediates and final 
target compounds is given below;  
4.3.1 Synthesis of (S)-2-acetamido-3-phenylpropanoic acid (33) 
 
To a 1.2 M solution phenylalanine in methanol was added acetic anhydride and the mixture 
was reflux for 6 hours. After cooling to room temperature, all the volatiles were removed 
at reduced pressure and the resultant colorless oil was kept overnight at -18 oC and resultant 
solid was filtered to obtained 33 as a colorless crystalline solid (Yield: 95 %) [126]. IR 
(neat): 3329.9, 3088.1, 3034.3, 2936.1, 2913.1, 1701.3, 1554.6, 1437.0, 1277.3, 1246.6, 
1115.7, 976.8, 706.1 cm-1. 1H-NMR (500 MHz, DMSO): δ 1.76 (s; 3H; CH3), 2.83-2.79 
(dd; J= 9.45 Hz, 1H, CH2-CH), 3.05-3.01 (dd, J=4.8 Hz, 1H, CH-CH2), 4.50 (m, 1H, CH-
CH2), 7.19-7.10 (m, 5H, Ar-H). 
13C-NMR (500 MHz, DMSO): δ 22.34 (CH2-CH), 36.82 
(COCH3), 53.59 (CH-CH2), 126.36 (Carom), 128.15 (Carom), 129.05 (Carom), 137.80 (Carom), 
169.19 (CONH), 173.21 (COOH). Anal. Calcd for C11H13NO3 (207.09): C 63.76, H 6.32, 




4.3.2 Synthesis of (S)-2-(methylsulfonamido)-3-phenylpropanoic acid (34) 
 
To a solution of L-phenylalanine (2.0 g, 12.12 mmol) in 1N NaOH (15 mL) at 0 oC was 
added CH2Cl2 (5 mL) followed by the addition of methane sulphonyl chloride (1.130 mL) 
dropwise and mixture was stirred for 3 hours at 0 oC. The reaction was acidified to pH-3 
with 1N HCl and then extracted with EtOAc (30 mL). The organic layer was separated and 
dried over Na2SO4 and evaporated under vacuum to obtain the title compound 34 as a white 
solid (Yield: 70%) [127]. IR (neat): 3256.9, 3028.0, 2931.5, 1748.6, 1720.3, 1311.7, 
1028.7, 765.9 cm-1. 1H-NMR (500 MHz, CDCl3): δ 2.61 (s, 3H, CH3), 3.02-2.97 (dd, J= 
8.25 Hz, 1H, CH2-CH), 3.25-3.3.21(dd, J=4.85 Hz, 1H, CH-CH2), 4.41 (m, 1H, CH-CH2), 
5.08 (d, J=9.15 Hz, 1H, NH), 7.34-7.22 (m, 5H, Ar-H). 13C-NMR (500 MHz, CDCl3): δ 
38.99 (CH-CH2), 41.31 (CH-CH2), 57.03 (CH3), 127.56 (Carom), 128.84 (Carom), 129.56 
(Carom), 135.38 (Carom), 175.26 (COOH). Anal. Calcd for C10H13NO4S (243.06): C 49.37, 
H 5.39, N 5.76; Found: C 48.37, H 5.30, N 6.82. 
4.3.3 Synthesis of  (S)-2-Acetamido-3-(4-fluorophenyl)propanoic acid (35) 
 
To a solution of compound 30 (1 g, 5.46 mmol) in MeOH (7 mL) was added acetic 
anhydride (1.40 mL, 14.75 mmol) and the mixture was refluxed for 6 hours. The reaction 
was cooled to room temperature and all the volatiles were removed at reduced pressure. 
The residue was kept overnight in a refrigerator and then warmed up to the room 
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temperature to allow the recrystallization of the title compound as a colorless crystalline 
solid (yield 86%). M. p. 139-140 oC. IR (neat): 3367, 3025, 2953, 1720, 1625, 1581, 1451, 
1360, 1028 cm-1.  1H NMR (500 MHz, CDCl3): δ 1.89 (s, 3 H, COCH3), 2.92 (dd, J = 9.1, 
14.0 Hz, 1 H, CH2CH), 3.16 (dd, J = 5.5, 14.1 Hz, 1 H, CH2CH), 4.61 (m, 1 H, CH2CH), 
6.98 (t, J = 8.5 Hz, 2 H, 3'-H, 5'-H), 7.22 (m, 2 H, 2'-H, 6'-H), 8.09 (d, J = 6.2 Hz, 1 H, 
NH).  13C NMR (125.7 MHz, CDCl3): δ 22.27 (COCH3), 37.63 (CH2CH), 55.10 (CH2CH), 
115.99 (C-3', C-5'), 131.95 (C-2', C-6'), 134.45 (C-1'), 162.60 (C-4'), 173.10 (C=O), 174.54 
(C=O). Anal. Calcd. C11H12FNO3: (225.22): C 58.66, H 5.37, N 6.22; Found C 58.61, H 
5.41, N 6.14. 
4.3.4 Synthesis of (S)-3-(4-Fluorophenyl)-2-(methylsulfonamido)propanoic 
acid (36) 
 
To a cold solution of compound 30 (0.5 g, 2.73 mmol) in 1M NaOH (10 mL) at 0 oC was 
added CH2Cl2 (2 mL) followed by the dropwise addition of methane sulphonyl chloride 
(0.25 mL, 3.28 mmol). The reaction mixture was stirred for 3 hours at 0 oC, transferred 
into a separatory funnel, and washed with diethyl ether (10 mL). The aqueous layer was 
acidified to pH 3 with 1N HCl and extracted with EtOAc (10 mL x 2). The organic layer 
was dried over Na2SO4 and evaporated to get compound 36 as a colourless gummy solid 
(yield 80%). IR (neat): 3538, 3034, 2930, 1733, 1605, 1512, 1412, 1225 cm-1. 1H NMR 
(500 MHz, CD3OD): δ  2.70 (s, 3 H, SO2CH3), 2.91 (dd, J = 8.5, 13.7 Hz, 1 H, CH2CH), 
3.13 (dd, J = 5.2, 13.7 Hz, 1 H, CH2CH), 4.20 (m, 1 H, CH2CH), 7.01 (m, 2 H, 3'-H, 5'-H), 
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7.28 (m, 2 H, 2'-H, 6'-H). 13C NMR (125.7 MHz, CD3OD): δ = 39.11 (SO2CH3), 41.28 
(CH2CH), 58.90 (CH2CH), 116.03 (C-3', C-5'), 132.40 (C-2', C-6'), 134.27 (C-1'), 162.60 
(C-4'), 174.59 (C=O). Anal. Calcd. C10H12FNO4S (261.27): C 45.97, H 4.63, N 5.36; Found 
C 45.92, H 4.67, N 5.30. 
4.3.5 Synthesis of (S)-2-Acetamido-3-(pyridin-3-yl)propanoic acid (37) 
 
Following the same procedure adopted for the synthesis of 35, acetylation of compound 31 
gave compound 37 as a colourless sticky solid (yield 73%).  IR (neat): 3428, 3050, 2946, 
1732, 1668, 1606, 1512, 1370, 1226, 1060 cm-1.  1H NMR (500 MHz, CDCl3): δ 1.82 (s, 3 
H, COCH3), 2.90 (dd, J = 8.5, 14.0 Hz, 1 H, CH2CH), 3.17 (dd, J = 5.2, 14.0 Hz, 1 H, 
CH2CH), 4.54 (m, 1 H, CH2CH), 7.29 (m, 1 H, 5'-H), 7.67 (m, 1 H, 6'-H), 8.30 (m, 1 H, 4'-
H), 8.41 (d, J = 1.1 Hz, 1 H, 2'-H). 13C NMR (125.7 MHz, CDCl3): δ 22.39 (COCH3), 
35.91 (CH2CH), 55.34 (CH2CH), 125.10 (C-5'), 135.67 (C-6'), 139.26 (C-1'), 148.12 (C-
4'), 150.68 (C-2'), 172.92 (C=O). Anal. Calcd. C10H12N2O3 (208.21): C 57.68, H 5.81, N 
13.45; Found C 57.62, H 5.86, N 13.38. 
4.3.6 Synthesis of (S)-2-(Methylsulfonamido)-3-(pyridin-3-yl)propanoic 
acid (38) 
 
Following the same procedure adopted for the synthesis of 35, acylation of 31 produced 
compound 38 as a light yellow gum (yield 82%). IR (neat): 3475, 3427, 3062, 2955, 1750, 
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1582, 1435, 1322, 1150 cm-1. 1H NMR (500 MHz, CDCl3): δ 2.69 (s, 3 H, SO2CH3), 2.85 
(dd, J = 7.3, 13.7 Hz, 1 H, CH2CH), 3.05 (dd, J = 5.2, 13.7 Hz, 1 H, CH2CH), 3.46 (m, 1 
H, CH2CH), 7.34 (m, 1 H, 5'-H), 7.76 (m, 1 H, 6'-H), 8.36 (m, 1 H, 4'-H), 8.43 (d, J = 1.3 
Hz, 1 H, 2'-H). 13C NMR (125.7 MHz, CDCl3): δ 39.42 (SO2CH3), 39.75 (CH2CH), 58.71 
(CH2CH), 125.04 (C-5'), 136.77 (C-6'), 139.26 (C-1'), 147.86 (C-4'), 150.89 (C-2'), 181.15 
(C=O). Anal. Calcd. C9H12N2O4S (244.27): C 44.25, H 4.95, N 11.47; Found C 44.20, H 
4.99, N 11.40. 
4.3.7 Synthesis of (S)-2-Acetamido-3-(pyridin-4-yl)propanoic acid (39) 
 
Following the same procedure adopted for the synthesis of 35, acetylation of 32 gave 
compound 39 as a brown gum (yield 75%). IR (neat): 3441, 3054, 2926, 1738, 1664, 1609, 
1508, 1378, 1223, 1066 cm-1. 1H NMR (500 MHz, CD3OD): δ 1.85 (s, 3 H, COCH3), 3.01 
(dd, J = 8.8, 13.7 Hz, 1 H, CH2CH), 3.26 (dd, J = 5.5, 13.7 Hz, 1 H, CH2CH), 4.72 (m, 1 
H, CH2CH), 7.35 (d, J = 6.1 Hz, 2 H, 2'-H, 6'-H), 8.44 (d, J = 6.1 Hz, 2 H, 3'-H, 5'-H). 
13C 
NMR (125.7 MHz, CD3OD): δ 22.29 (COCH3), 37.92 (CH2CH), 54.21 (CH2CH), 126.50 
(C-2', C-6'), 149.38 (C-1'), 150.29 (C-3', C-5'), 173.11 (C=O), 175.27 (C=O). Anal. Calcd. 





4.3.8 Synthesis of (S)-2-(Methylsulfonamido)-3-(pyridin-4-yl)propanoic 
acid (40) 
 
Following the same procedure adopted for the synthesis of 35, acylation of 32 rendered 
compound 40 as a light yellow gum (yield, 85%).  IR (neat): 3500, 3073, 2923, 1702, 1607, 
1393, 1297, 1153 cm-1. 1H NMR (500 MHz, CD3OD): δ 2.85 (s, 3 H, SO2CH3), 2.98 (dd, 
J = 8.2, 13.7 Hz, 1 H, CH2CH), 3.15 (dd, J = 5.2, 13.7 Hz, 1 H, CH2CH), 4.02 (m, 1 H, 
CH2CH), 7.36 (d, J = 6.8 Hz, 2 H, 2'-H, 6'-H), 8.43 (d, J = 6.8 Hz, 2 H, 3'-H, 5'-H).
 13C 
NMR (125.7 MHz, CD3OD): δ 37.35 (CH2CH), 40.29 (SO2CH3), 60.32 (CH2CH), 126.96 
(C-2', C-6'), 149.47 (C-1'), 150.49 (C-3', C-5'), 176.85 (C=O). Anal. Calcd. C9H12N2O4S 
(244.27): C 44.25, H 4.95, N 11.47; Found C 44.19, H 5.00, N 11.41. 
4.3.9 (S)-2-acetamido-3-(4-methoxyphenyl)propanoic acid (42) 
The synthesis of (S)-2-acetamido-3-(4-methoxyphenyl)propanoic acid (42) started from 
the L-tyrosine and converted into a methyl ester of L-tyrosine hydrochloride. Further, this 
ester was modified into an N-acetylated product 42a and then to O-alkylated 42b followed 






4.3.10 Synthesis of (S)-methyl 2-acetamido-3-(4-hydroxyphenyl)propanoate 
(42a) 
 
To a solution of pyridine (10 mL) and acetic anhydride (11 mL, 120 mmol) at 0 oC was 
added L-tyrosine-methyl ester HCl (5.0 g, 23 mmol) portion wise. The reaction was then 
allowed to run overnight at room temperature. The reaction was quenched by adding ice-
water (100 mL) and then extracted CH2Cl2 (15 mL x 4) and the organic layer was 
sequentially washed with sat. NaHCO3 (20 mL), 0.1 M HCl (20 mL) and H2O (20 mL). 
The organic layer was dried over MgSO4 and evaporated under vacuum to get the title 
compound 42a as white solid (yield, 87%) [133, 134]. IR (neat):  3551.3, 3363.6, 3157.5, 
3015.3, 2958.3, 1730.9, 1663.9, 1548.8, 1443.8, 1378.3, 1048.1, 833.1 cm-1. 1H NMR (500 
MHz, CDCl3): δ 1.97 (s, 3H, CH3), 3.01-2.97 (dd, J=5.5Hz, J= 7.6 Hz, CH-CH2), 3.08-3.04 
(dd, J=5.8 Hz, J= 7.6Hz, CH-CH2), 4.84 (m, 1H, CH-CH2), 6.73 (d, J=8.5 Hz, Ar-H), 6.93 
(d, J=8.5 Hz, Ar-H). 13C-NMR (500 MHz, CDCl3): δ 22.90 (CH-CH2), 37.0 (COCH3), 
52.14 (OCH3), 53.19 (CH-CH2), 115.50 (Carom), 126.70 (Carom), 130.01 (Carom), 155.52 
(Carom), 170.70 (CONH), 172.3 (COOH). Anal. Calcd. C12H15NO4 (237.10): C 60.75, H 





4.3.11 Synthesis of (S)-methyl 2-acetamido-3-(4-methoxyphenyl)propanoate 
(42b) 
 
To a solution of 42a (3.23 g, 10.93 mmol) in DMF (40 mL) was added K2CO3 (2.26 g, 
16.39 mmol) and after the reaction being stirred for 10 minutes, iodomethane (1.71 mL, 
27.32 mmol) was added and the reaction was then allowed to run overnight at room 
temperature. After completion of the reaction (TLC), the reaction was quenched with cold 
1N HCl (25 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was 
washed with brine (15 mL x 2), dried over anhydrous Na2SO4 and evaporated under vaccuo 
to obtain the title compound 42b as a colourless sticky solid. IR (neat): 3273.5, 3079.4, 
3013.0, 2960.0, 2842.3, 1759.4, 1646.8, 1560.9, 1453.9, 1375.5, 1184.3, 1027.3, 826.7 cm-
1. 1H NMR (500 MHz, CDCl3): δ 1.90 (s, 3H, CH3), 2.96-2.93 (dd: J= 5.8 Hz, 1H, CH-
CH2), 3.02-2.98 (dd, J=6.7 Hz, J=6.7 Hz, 1H, CH-CH2), 3.64 (s, 3H, CH3), 3.70 (s, 3H, 
CH3), 4.75 (m, 1H, CH-CH2), 6.78 (d, J=8.5, 6.5 Hz, 2H, Ar-H), 6.98 (d, J=8.5, 9.4Hz, 2H, 
Ar-H). 13C-NMR (500 MHz, CDCl3): δ 22.90 (CH-CH2), 31.30 -COCH3), 52.14 (OCH3), 
53.19 (CH-CH2), 55.062 (OCH3), 113.82 (Carom), 127.70 (Carom), 130.08 (Carom), 158.52 
(Carom), 169.70 (CONH), 172.13 (COOH). Anal. Calcd. C13H17NO4 (251.12): C 62.14, H 





4.3.12 (S)-2-acetamido-3-(4-methoxyphenyl)propanoic acid (42) 
 
To a solution of compound 42b (0.88 g, 4 mmol) in a mixture of THF: MeOH: H2O (6:2:1, 
15 mL) was added LiOH (0.1 g, 8 mmol) and the mixture was stirred for overnight at room 
temperature. The pH of mixture was adjusted to 5-6 with 1M HCl and was portioned 
between ethyl acetate and water. Then separated the organic layer and washed with brine, 
dried over Na2SO4 and evaporated to dryness under reduced pressure. Column 
chromatography on silica gel eluting with ethyl acetate: hexanes (1:1) and then changing 
to (2:1) gave the titled compound 42 (Yield, 86%). IR (neat): 3322.7, 3075.5, 3013.1, 
2927.4, 2831.7, 1706.8, 1617.0, 1555.3, 1512.6, 1452.7, 1327.7, 1035.5, 843.3 cm-1. 1H 
NMR (500 MHz, CDCl3): δ 2.00 (s, 3H, CH3), 3.10-3.06 (dd, J=5.75Hz, 1H, CH-CH2), 
3.18-3.14 (dd, J=5.5 Hz, 1H, CH-CH2), 3.78 (s, 3H, CH3), 4.80 (m, 1H, CH-CH2), 5.98 (d, 
J= 7.35 Hz, NH),  6.84 (d, J=8.25 Hz, 2H, Ar-H), 7.08 (d, J=8.25 Hz, 2H, Ar-H). 13C-NMR 
(500 MHz, CDCl3): δ 23.09 (CH-CH2), 36.29 (OCH3), 53.38 (CH-CH2), 55.21 (OCH3), 
114.09 (Carom), 127.46 (Carom), 130.31 (Carom), 158.87 (Carom), 170.75 (CONH), 173.97 
(COOH). Anal. Calcd. C12H15NO4 (237.10): C 60.75, H 6.37, N 5.90, O 26.97; Found C 
62.25, H 5.50, N 6.87, O 25.47. 
4.3.13 (S)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoic 
acid (43) 
The synthesis of (S)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoic acid 
(43) was accomplished from methyl ester of L-tyrosine hydrochloride by the operations of 
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N-acetylation with boc anhydride to obtain 43a, which in turn was subjected to O-
alkylation to furnish the desired intermediate 43.  
4.3.14 Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(4-
hydroxyphenyl)propanoate (43a) 
 
To a solution of (S)-tyrosine methyl ester hydrochloride (41) (2.51 g, 10.84 mmol) in a 
mixture of THF/methanol (50 ml/15 ml) was added NaHCO3 (1.82 g, 21.68 mmol) 
followed by the addition of solution of di-tert-butyl dicarbonate (2.366 g, 10.84 mmol) 
dissolved in THF (20 ml). The reaction mixture was stirred at room temperature for 22 h 
and the solvents were evaporated under vacuo. The residue was dissolved in CH2Cl2, 
washed with water and dried over MgSO4. The filtrate was concentrated under reduced 
pressure and recrystallization from CH2Cl2 provided the title compound 43a as white 
crystalline solid (yield, 98%) [135, 136]. IR (neat): 3389.7, 3002.6, 2978.3, 2952.0, 1717.2, 
1688.9, 1617.0, 1446.1, 1396.1, 1159.3, 994.0, 830.1 cm-1. 1H-NMR (500 MHz, CDCl3):  
δ 1.42 (s, 9H, (CH3)3), 2.98-2.95 (dd, J=7.05, 3.05-3.02 (dd, J=5.5, 9.5 Hz, 1H, CH-CH2), 
3.71 (s, 3H, CH3), 4.05 Hz, 1H, CH-CH2), 4.54 (m, 1H, CH-CH2), 5.01 (d: J= 9.45Hz, 1H, 
NH), 5.62 (s, 1H, OH), 6.74 (d, J=7.65 Hz, 2H, Ar-H), 6.97 (d, J=8.25 Hz, 2H, Ar-H). 13C-
NMR (500 MHz, CDCl3): δ 28.5 ((CH3)3), 37.7 (CH-CH2), 52.4 (OCH3), 54.8 (CH-CH2), 
80.4 (OC(CH3)3), 115.7 (Carom), 127.7 (Carom), 130.5 (Carom),155.3 (Carom), 155.5 
(COOCH3), 172.8 (CONH). Anal. Calcd. C15H21NO5 (295.14): C 61.00, H 7.17, N 4.74.09; 
Found C 61.50, H 5.55, N 6.87. 
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4.3.15 Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(4-
methoxyphenyl)propanoate (43b) 
 
To a solution of 43a (1.62 g, 5.45 mmol) in DMF (30 mL) was added K2CO3 (1.13 g, 8.202 
mmol) and after the reaction being stirred for 10 minutes, iodomethane (0.86 mL, 12.65 
mmol) was added to the mixture. The reaction was stirred overnight at room temperature 
and then transferred in separating funnel and extracted ethyl acetate (15 mL × 3) and the 
organic layer was washed with brine (15 mL). The organic layer was dried over anhydrous 
Na2SO4 and evaporated under reduced pressure to get the title compound 43b as colourless 
sticky solid. IR (neat): 3445.9, 3347.9, 2978.7, 2929.8, 1717.7, 1513.9, 1513.9, 1397.4, 
1368.8, 1249.4, 1167.1, 1032.1, 829.7 cm-1. 1H-NMR (500 MHz, CDCl3):  δ 1.42 (s, 9H, 
(CH3)3), 3.01-2.98 (dd, J=7.65 Hz, J=5.72 Hz, 1H, CH-CH2), 3.07-3.03 (dd, J=6.75 Hz, 
J=7.05 Hz, 1H, CH-CH2), 3.71(s, 3H, CH3), 3.78 (s, 3H, CH3), 4.53 (m, 1H, CH-CH2), 
4.97(d, 1H, NH), 6.83 (d, J=8.5 Hz, 2H, Ar-H), 7.04 (d, J=8.2 Hz, 2H, Ar-H). 13C-NMR 
(125.7 MHz, CDCl3): δ 28.20 ((CH3)3), 37.34 (CH-CH2), 52.05 (OCH3), 54.47 (CH-CH2), 
55.10 (OCH3), 79.75 (OC(CH3)3), 113.88 (Carom), 127.86 (Carom), 130.18 (Carom), 155.03 
(Carom), 158.56 (Carom), 172.34 (COOCH3), 192.45 (CONH). Anal. Calcd. C16H23NO5 








To a solution of 42b (0.450 g, 1.464 mmol) in a mixture of THF: MeOH: H2O (3:1:1, 15 
mL) was added LiOH (0.307 g, 27.34 mmol) and the mixture was stirred overnight at room 
temperature. The mixture was carefully acidified with 1M HCl to pH and then ethyl acetate 
(15 mL × 3). The organic layer was washed with brine (10 mL), dried over Na2SO4 and 
evaporated under reduced pressure. Column chromatography on silica gel eluting with 
ethyl acetate: hexanes (1:1) and then changing to (2:1) gave the titled compound 43 as 
sticky white solid (yield, 86%). IR (neat): 3439.6, 3346.5, 2979.2, 2933.0, 1719.4, 1614.2, 
1513.9, 1397.6, 1368.7, 1164.1, 1032.7, 829.7 cm-1. 1H NMR (500 MHz, CDCl3):  δ 1.42 
(s, 9H, (CH3)3)), 3.04-3.00 (dd, J=7.65, 9.75 Hz, 1H, CH-CH2), 3.15-3.10 (dd, J=6.75, 9.75 
Hz, 3.78 (s, 3H, CH3), 1H, CH-CH2), 4.53 (m, 1H, CH-CH2), 4.92 (d, 1H, NH), 6.85 (d, 
J=8.2 Hz, 2H, Ar-H), 7.10 (d J=8.25 Hz,2H, Ar-H). 13C-NMR (500 MHz, CDCl3): δ 1.39 
((CH3)3), 27.00 (CH-CH2), 55.85 (CH-CH2), 56.65 (OCH3), 81.77 (OC (CH3)3), 115.50 
(Carom), 131.78 (Carom), 156.92 (Carom), 160.17 (Carom), 176.80 (COOH), 190.10 (CO). Anal. 
Calcd. C15H21NO5 (295.14): C 61.00, H 7.17, N 4.74; Found C 61.40, H 6.35, N 5.67. 
4.3.17 (S)-3-(4-Methoxyphenyl)-2-(methylsulfonamido)propanoic acid (44) 
The synthesis of (S)-3-(4-Methoxyphenyl)-2-(methylsulfonamido)propanoic acid (44) was 
achieved from the acylation of methyl ester of L-tyrosine hydrochloride (41) with 
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methanesulfonyl chloride to produce 44a, which was subjected to the operations of O-
alkylation followed by basic hydrolysis of ester function.  
4.3.18 Synthesis of (S)-Methyl 3-(4-hydroxyphenyl)-2-
(methylsulfonamido)propanoate (44a) 
 
To a cold suspension of methyl ester of L-tyrosine hydrochloride (41) (0.5 g, 2.16 mmol) 
in CH2Cl2 (15 mL) was added trimethylamine (1.20 mL, 8.6 mmol) followed by the 
dropwise addition of a solution of methane sulphonyl chloride (0.25 mL, 3.24 mmol) in 
CH2Cl2 (2 mL). The reaction mixture was stirred overnight at room temperature and 
quenched with water (10 mL) followed by the pH of the mixture was adjusted to 4-5 with 
dilute HCl. The organic layer was separated, dried over Na2SO4 and evaporated under 
reduced pressure to get the title compound 44a as a white solid (yield 90%). M. p. 102-103 
oC. IR (neat): 3310, 3022, 2941, 1738, 1506, 1451, 1367, 973 cm-1. 1H NMR (500 MHz, 
CDCl3): δ 2.76 (s, 3 H, SO2CH3),
 3.06 (dd, J = 7.0, 14.0 Hz, 1 H, CH2CH), 3.18 (dd, J = 
5.5, 14.0 Hz, 1 H, CH2CH), 3.79 (s, 3 H, OCH3), 4.41 (m, 1 H, CH2CH), 4.93 (d, J = 9.15 
Hz, 1 H, NH), 6.70 (d, J = 8.5 Hz, 2 H, 3'-H, 5'-H), 6.96 (d, J = 8.5 Hz, 2 H, 2'-H, 6'-H). 
13C NMR (125.7 MHz, CDCl3): δ 38.80 (SO2CH3), 41.31 (CH2CH), 52.95 (OCH3), 56.84 
(CH2CH), 122.37 (C-3', C-5'), 131.14 (C-1'), 134.80 (C-2', C-6'), 148.40 (C-4'), 171.53 
(C=O).  Anal. Calcd. C11H15NO5S (271.31):: C 48.34, H 5.53, N 5.12; Found C 48.28, H 
5.47, N 5.05. 
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4.3.19 Synthesis of (S)-Methyl 3-(4-methoxyphenyl)-2-
(methylsulfonamido)propanoate (44b) 
 
To a solution of compound 44a (0.7 g, 2.56 mmol) in DMF (15 mL) was added NaHCO3 
(0.43 g, 5.12 mmol) was added at room temperature and after the mixture being stirred for 
10 minutes, CH3I (0.32 mL, 5.12 mmol) was added. The reaction mixture was stirred 
overnight at room temperature followed by the addition of H2O (10 mL) and 1M HCl (10 
mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with brine, 
dried over Na2SO4 and evaporated under reduced pressure to obtain the title compound 44b 
as a colorless thick gum (yield 92%). IR (neat): 3033, 2971, 2936, 1738, 1660, 1506, 1362, 
1146 cm-1. 1H NMR (500 MHz, CDCl3): δ 2.72 (s, 3 H, SO2CH3), 3.00 (dd, J = 7.3, 13.9 
Hz, 1 H, CH2CH), 3.10 (dd, J = 5.8, 13.9 Hz, 1 H, CH2CH), 3.78 (s, 3 H, OCH3), 3.79 (s, 
3 H, OCH3), 4.37 (m, 1 H, CH2CH), 6.85 (d, J = 8.5 Hz, 2 H, 3'-H, 5'-H), 7.10 (d, J = 8.5 
Hz, 2 H, 2'-H, 6'-H). 13C NMR (125.7 MHz, CDCl3): δ 38.57 (SO2CH3), 41.35 (CH2CH), 
52.72 (OCH3), 55.23 (OCH3), 57.15 (CH2CH), 114.17 (C-3', C-5'), 127.09 (C-1'), 130.49 
(C-2', C-6'), 158.94 (C-4'), 171.9 (C=O). Anal. Calcd. C12H17NO5S (287.33): C 50.16, H 





4.3.20 Synthesis of (S)-3-(4-Methoxyphenyl)-2-(methylsulfonamido) 
propanoic acid (44) 
 
To a solution of 44b (0.86 g, 3 mmol) in a mixture of THF:MeOH:H2O (6:2:1, 15 mL) was 
added LiOH.H2O (0.38 g, 9 mmol) and the mixture was stirred overnight at room 
temperature followed by the addition of 1M HCl to adjust the pH of the reaction to 6. The 
mixture was extracted with EtOAc (20 mL) and the organic layer was washed with brine, 
dried over Na2SO4 and evaporated. Column chromatography on silica gel eluting with ethyl 
acetate:hexanes (1:1) and then changing to (2:1) gave the titled compound 44 as a thick 
brown gum (yield 86%). IR (neat): 3541, 3281, 3025, 2936, 1735, 1609, 1513, 1307, 1149 
cm-1. 1H NMR (500 MHz, CDCl3): δ 2.67 (s, 3 H, SO2CH3), 2.96 (dd, J = 7.6, 14.0 Hz, 1 
H, CH2), 3.16 (dd, J = 4.5, 14.0 Hz, 1 H, CH2), 3.78 (s, 3 H, OCH3), 4.35 (m, 1 H, CH), 
5.10 (br. s, 1 H, NH), 6.86 (d, J = 8.5 Hz, 2 H, aromatic H), 7.16 (d, J = 8.5 Hz, 2 H, 
aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 38.07 (SO2CH3), 41.23 (CH2CH), 55.28 
(OCH3), 57.48 (CH2CH), 114.18, 127.74, 130.66, 158.85 (Carom), 175.10 (C=O). Anal. 
Calcd. C11H15NO5S (273.31): C 48.34, H 5.53, N 5.12; Found C 48.29, H 5.59, N 5.05. 
4.3.21 Synthesis of 2-(5-(3-((tert-Butoxycarbonyl)amino)propoxy)-1-(3,4-




To a solution of 47 (2.0 g, 5.11 mmol) in DMF (20 mL) was sequentially added K2CO3 
(0.92 g, 6.66 mmol) followed by tert-butyl-(3-bromoropropyl)carbamate (1.45 g, 6.12 
mmol) and the mixture was further stirred for 8 hours at room temperature. The reaction 
was diluted with H2O (15 mL) and extracted with EtOAc (50 mL). The organic layer was 
washed with H2O (10 mL), brine (10 mL), dried over Na2SO4 and concentrated under 
reduced pressure. Column chromatography of the dark orange oily material, eluting with 
EtOAc-hexane (3:1) yielded compound 54 as a light yellow oil (yield 59%). IR (neat): 
3361, 3040, 2973, 1740, 1710, 1675, 1592, 1481, 1386, 1234, 1029 cm-1. 1H NMR (500 
MHz, CDCl3): δ 1.44 (s, 9 H, OC(CH3)3), 1.96 (s, 3 H, COCH3), 2.27 (pent, 2H, 
CH2CH2CH2), 2.98 (t, J = 7.3 Hz, 2 H, ArCH2), 3.29 (m, 2 H, NCH2), 4.04 (t, J = 6.1 Hz, 
2 H, OCH2), 4.22 (t, J = 7.0 Hz, 2 H, OCH2), 7.39 (dd, J = 4.85, 7.9 Hz, 1 H, aromatic H), 
7.66 (dd, J = 2.4, 8.5 Hz, 1 H, aromatic H), 7.94 (d, J = 2.4 Hz, 1 H, aromatic H), 8.00-
8.03 (m, 2 H, aromatic H), 8.64 (dd, J = 2.1, 6.5 Hz, 1 H, aromatic H), 8.93 (d, J =1.8 Hz, 
1 H, aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 20.84 (COCH3), 21.25 (Ar-CH2), 28.38 
(OC(CH3)3), 30.30 (CH2CH2CH2), 36.50 (NCH2), 65.39 (OCH2), 73.34 (OCH2), 79.44 
(OC(CH3)3), 103.27, 120.47, 123.62, 123.70, 129.58, 130.86, 133.23, 135.12, 137.62, 
148.19, 148.46, 149.10, 152.06 (all Carom), 155.97 (C=O), 170.97 (C=O). Anal. Calcd. 
C26H30Cl2N4O5 (549.45): C 56.84, H 5.50, N 10.20; Found C 56.78, H 5.55, N, 10.14. 
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4.3.22 Synthesis of tert-Butyl (3-((1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-
3-(pyridin-3-yl)-1H-pyrazol-5-yl)-oxy)propyl)carbamate (55) 
 
To a cold solution of compound 54 (0.83 g, 1.64 mmol) in a mixture of THF (10 mL) and 
MeOH (5 mL) at 0 oC was added a solution of KOH (0.34 g, 6.06 mmol) in H2O (5 mL). 
After being stirred for 15 minutes at 0 oC, the reaction was further stirred for 45 minutes at 
room temperature. Upon completion of the reaction (TLC), the mixture was concentrated 
under reduced pressure and diluted with EtOAc (30 mL) and successively washed with 
H2O (10 mL) and brine (10 mL). The organic layer was dried over Na2SO4 and evaporated 
to dryness under reduced pressure. Column chromatography of the light orange oil 
material, eluting with EtOAc:hexan (6:4) gave the title compound 55 as a light yellow gum 
(yield 85%). IR (neat): 3345, 3055, 2974, 1691, 1593, 1482, 1366, 1169 cm-1. 1H NMR 
(500 MHz, CDCl3): δ 1.44 (s, 9 H, OC(CH3)3), 1.91 (pent, 2 H, CH2CH2CH2), 2.86 (t, J = 
6.7 Hz, 2 H, Ar-CH2), 3.36 (m, 2 H, NCH2), 3.77 (t, J = 5.8 Hz, 2 H, OCH2), 4.02 (t, J = 
5.8 Hz, 2 H, OCH2), 4.81 (br. s, 1 H, NH/OH), 7.36 (dd, J = 4.8, 7.9 Hz, 1 H, aromatic H), 
7.54 (d, J = 8.5 Hz, 1 H, aromatic H), 7.67 (dd, J = 2.4, 8.5 Hz, 1 H, aromatic H), 7.96 (d, 
J = 2.4 Hz, 1 H, aromatic H), 8.00 (dd, J = 5.8, 7.9 Hz, 1 H, aromatic H), 8.61 (dd, J = 1.5, 
4.9 Hz, 1 H, aromatic H), 8.91 (d, J = 2.1 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, 
CDCl3): δ 23.30 (Ar-CH2), 28.36 (OC(CH3)3), 30.28 (CH2CH2CH2), 37.25 (NCH2), 63.37 
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(OCH2), 73.30 (OCH2), 79.44 (OC(CH3)3), 102.68, 120.94, 123.54, 123.68, 129.46, 
130.83, 133.21, 134.98, 137.58, 148.26, 148.59, 149.35, 152.26 (all Carom), 155.97 (C=O). 
Anal. Calcd. C24H28Cl2N4O4 (507.41): C 56.81, H 5.56, N 11.04; found C 56.76, H 5.50, 
N 11.97. 




To an ice-cold solution of compound 55 (0.41 g, 0.81 mmol) in anhydrous CH2Cl2 (10 mL) 
was added Et3N (0.34 mL, 2.44 mmol) and after being stirred for 15 minutes, methane 
sulphonyl chloride (0.094 mL, 1.212 mmol) was added to the mixture. The stirring was 
continued for 1 hour at 0 0C and the mixture then diluted with H2O (5 mL) followed by the 
addition of 1M HCl (5 mL). The organic layer was separated, dried over Na2SO4 and 
evaporated under reduced pressure to obtain the target compound 56 as a crystalline white 
solid (yield 98%). M. p. 94-95 oC. IR (neat): 3356, 3038, 3015, 2986, 1682, 1590, 1483, 
1384, 1172 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.44 (s, 9 H, OC(CH3)3), 1.93 (pent, 2 H, 
CH2CH2CH2), 3.00 (s, 3 H, SO2CH3), 3.14 (t, J = 6.4 Hz, 2 H, Ar-CH2), 3.29 (m, 2 H, 
NCH2), 4.02 (t, J = 6.1 Hz, 2 H, OCH2), 4.37 (t, J = 6.7 Hz, 2 H, OCH2), 4.72 (br. s, 1 H, 
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NH), 7.59 (d, J = 8.5 Hz, 1 H, aromatic H), 7.65 (dd, J = 2.4, 8.8 Hz, 1 H, aromatic H), 
7.86 (m, 1 H, aromatic H), 7.92 (d, J = 2.4 Hz 1 H, aromatic H), 8.63 (m, 1 H, aromatic 
H), 8.70 (d, J = 5.2 Hz, 1 H, aromatic H), 9.09 (d, J = 1.2 Hz, 1 H, aromatic H). 13C NMR 
(125.7 MHz, CDCl3): δ 23.32 (Ar-CH2), 28.38 (OC(CH3)3), 30.46 (CH2CH2CH2), 37.70 
(SCH3), 38.35 (NCH2), 68.43 (OCH2), 73.78 (OCH2), 79.59 (OC(CH3)3), 102.56, 121.15, 
123.91, 126.23, 131.10, 131.89, 132.99, 133.52, 137.00, 141.11, 141.26, 141.55, 144.57, 
152.92 (all Carom), 156.03 (C=O). Anal. Calcd. C25H30Cl2N4O6S (584.13): C 51.28, H 5.16, 
N 9.57; Found: C 51.22, H 5.09, N 9.63.  




To a solution of compound 56 (1.25 g, 2.14 mmol) in DMF (15 mL) at 0 oC was added 
NaSCH3 (0.6 g, 8.57 mmol) and the mixture was stirred for 2 hours at room temperature. 
The reaction was diluted with EtOAc (30 mL) and washed with H2O (10 mL) and brine 
(10 mL x 2).  The light yellow residue was resolved over column chromatography, eluting 
with EtOAc: hexane (6:4) to produce the title compound 57 as a light brown gum (yield 
78%). IR (neat): 3402, 3092, 2975, 1696, 1590, 1483, 1386, 1171 cm-1. 1H NMR (500 
MHz, CDCl3): δ 1.43 (s, 9 H, OC(CH3)3), 1.95 (pent, 2 H, CH2CH2CH2), 2.10 (s, 3 H, 
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SCH3), 2.71 (t, J = 7.3 Hz, 2 H, SCH2), 2.95 (t, J = 7.3 Hz, 2 H, Ar-CH2), 3.28 (m, 2 H, 
NCH2), 4.04 (t, J = 6.1 Hz, 2 H, OCH2), 7.59 (d, J = 8.8 Hz, 1 H, aromatic H), 7.65 (dd, J 
= 2.4, 8.8 Hz, 1 H, aromatic H), 7.89 (m, 1 H, aromatic H), 7.93 (d, J = 2.4 Hz, 1 H, 
aromatic H), 8.65 (d, J = 7.9 Hz, 1 H, aromatic H), 8.71 (d, J = 4.6 Hz, 1 H, aromatic H), 
9.12 (d, J = 2.4 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 15.90 (SCH3), 
23.21 (Ar-CH2), 28.44 (OC(CH3)3), 30.96 (CH2CH2CH2), 34.15 (SCH2), 36.97 ((CH2CH)), 
38.49 (NCH2), 73.54 (OCH2), 79.33 (OC(CH3)3), 104.85, 120.89, 123.67, 125.66, 131.06, 
131.61, 133.50, 137.17, 139.68, 142.50, 143.50, 144.82, 152.60 (all Carom), 156.20 (C=O). 
Anal. Calcd. C25H30Cl2N4O3S (537.50): C 55.86, H 5.63, N 10.42; found C 55.80, H 5.68, 
N 10.36. 




To a solution of compound 57 (0.37 g, 0.69 mmol) in anhydrous CH3OH (10 mL) at 0 
oC 
was added acetyl chloride (1 mL) and the reaction mixture was stirred overnight at room 
temperature. The volatiles were evaporated under reduced pressure and then triturated with 
diethyl ether to get a compound 58 as a very hygroscopic light yellow solid (yield 98%). 
IR (neat): 3419, 2962, 1624, 1586, 1481, 1140 cm-1. 1H NMR (500 MHz, CD3OD): δ 1.98 
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(s, 3 H, SCH3), 2.00 (m, 2 H, CH2CH2CH2), 2.64 (t, J = 7.3 Hz 2 H, SCH2), 2.95-3.00 (m, 
4H, Ar-CH2, NCH2), 4.09 (t, J = 6.15 Hz, 2 H, OCH2), 7.65 (m, 2 H, aromatic H), 7.90 (d, 
J = 2.2 Hz, 1 H, aromatic H), 8.07 (m, 1 H, aromatic H), 8.77 (d, J = 5.8 Hz, 1 H, aromatic 
H), 8.85 (d, J = 8.2 Hz, 1 H, aromatic H), 9.12 (d, J = 2.4 Hz, 1 H, aromatic H). 13C NMR 
(125.7 MHz, CD3OD): δ 15.66 (SCH3), 23.65 (Ar-CH2), 29.02 (CH2CH2CH2), 35.05 
(SCH2), 38.01 (NCH2), 74.02 (OCH2), 108.02, 123.38, 125.60, 128.63, 131.18, 132.50, 
132.78, 137.10, 141.73, 142.43, 145.02, 153.56, 156.13 (all Carom). Anal. Calcd. 
C20H23Cl3N4OS (473.85): C 50.69, H 4.89, N 11.82; Found C 50.63, H 4.95, N 11.74. 




To a solution of mixture of compounds 58 (0.15 g, 0.32 mmol) and 33 (0.068 g, 0.33 mmol) 
in CH2Cl2 (10 mL) was sequentially added hydroxybenzotriazole (0.050 g, 0.33 mmol), N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.084 g, 0.44 mmol) and 
Et3N (0.15 mL, 1.1 mmol) and the mixture was stirred overnight at room temperature. The 
reaction was diluted with ethyl acetate (20 mL) and washed with sat. NaHCO3 (10 mL), 
H2O (10 mL) and brine (10 mL). The organic layer was dried over Na2SO4 and evaporated 
under reduce pressure. Column chromatography purifications of light yellow oily material, 
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eluting with EtOAc: hexane (8:2) gave the product as a light green solid (yield 69%). M. 
p. 125-126 oC. −[𝛼]D
20= –3.1 (c = 0.0051, EtOH). IR (neat): 3255, 3072, 2952, 1670, 1639, 
1592, 1563, 1480.7, 1368, 1139, 1082 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.83 (pent, 2 
H, CH2CH2CH2), 1.97 (s, 3 H, COCH3), 2.08 (s, 3 H, SCH3), 2.67 (t, J = 7.1 Hz, 2 H, 
SCH2), 2.91 (t, J = 7.9 Hz, 2H, ArCH2), 3.10 (dd, J = 8.2, 13.7 Hz, 1 H, CH2CH), 3.11 (dd, 
J = 5.8, 13.7 Hz, 1 H, CH2CH), 3.31 (m, 2 H, NCH2), 3.87 (t, J = 6.2 Hz, 2 H, OCH2), 4.58 
(m, 1 H, CH2CH), 6.23-6.29 (br. s, 2 H, 2NH), 7.18-7.22 (m, 2 H, aromatic H), 7.25-7.29 
(m, 3 H, aromatic H), 7.57 (d, J = 8.8 Hz, 1 H, aromatic H), 7.63 (dd, J = 2.4, 8.8 Hz, 1 H, 
aromatic H), 7.76 (m, 1 H, aromatic H), 7.90 (d, J = 2.4 Hz, 1 H, aromatic H), 8.49 (d, J = 
8.0 Hz, 1 H, aromatic H), 8.73 (d, J = 6.5 Hz, 1 H, aromatic H), 9.10 (s, 1 H, aromatic H). 
13C NMR (125.7 MHz, CDCl3): δ 15.89 (SCH3), 23.05 (COCH3), 23.21 (Ar-CH2), 30.93 
(CH2CH2CH2), 34.19 (SCH2), 36.15 (CH2CH), 38.38 (NCH2), 54.46 (CH2CH), 73.21 
(OCH2), 106.19, 121.06, 123.72, 127.06, 128.68, 129.21, 129.42, 131.00, 131.33, 133.32, 
136.62, 137.31, 152.12 (all Carom), 170.10 (C=O), 171.10 (C=O). Anal. Calcd. 
C31H33Cl2N5O3S (626.60): C 59.42, H 5.31, N 11.18; Found C 59.36, H 5.37, N 11.10. 






Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 34 
gave the title compound 7 as a colorless solid (yield 57%). M. p. 130-131 oC.−[𝛼]D
20 = –
38.4 0.0025, EtOH). IR (neat): 3376, 3280, 3062, 2920, 1664. 1592, 1566, 1482, 1457, 
1317, 1149 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.95 (pent, 2 H, CH2CH2CH2), 2.08 (s, 3 
H, SCH3), 2.54 (s, 3 H, SO2CH3), 2.70 (t, J = 6.7 Hz, 2 H, SCH2), 2.89 (dd, J = 7.2, 13.7 
Hz, 1 H, CH2CH), 2.97 (t, J = 7.6 Hz, 2 H, ArCH2), 3.31 (m, 2 H, NCH2), 3.41 (dd, J = 
5.6, 13.7 Hz, 1 H, CH2CH), 4.03 (t, J = 6.4 Hz, 2 H, OCH2), 4.08 (m, 1 H, CH2CH), 5.73 
(br. s, 1 H, NH), 7.20-7.24 (m, 2 H, aromatic H), 7.25-7.30 (m, 3 H, aromatic H), 7.57 (d, 
J = 8.8 Hz, 1 H, aromatic H), 7.66 (dd, J = 2.4, 8.8 Hz, 1 H, aromatic H), 7.90 (m, 1 H, 
aromatic H), 7.95 (m, 1 H, aromatic H), 8.49 (d, J = 7.6 Hz, 1 H, aromatic H), 8.76 (d, J = 
6.5 Hz, 1 H, aromatic H), 9.10 (s, 1 H, aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 
15.66 (SCH3), 23.17 (Ar-CH2), 29.54 (CH2CH2CH2), 33.98 (SCH2), 36.45 (CH2CH), 38.66 
(NCH2), 40.03 (SO2CH3), 59.12 (CH2CH), 72.97 (OCH2), 106.76, 121.03, 123.57, 123.69, 
127.63, 129.13, 129.39, 129.62, 130.74, 130.89, 133.14, 134.92, 136.38, 137.66, 147.88, 
148.52, 149.34, 151.73 (all Carom), 170.46 (C=O). Anal. Calcd. C30H33Cl2N5O4S2 (662.65): 
C 54.38, H 5.02, N 10.57; Found C 54.33, H 5.07, N, 10.50. 






Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 35 
gave the title compound 8 as a colorless solid (yield 67%). M. p. 117-118 oC. – [α]D
20 = –
5.6 (c = 0.0.005, EtOH). IR (neat): 3505, 3272, 3066, 2921, 1892, 1654, 1593.3, 1509, 
1482, 1368, 1220, 1132 cm-1. 1H NMR (500 MHz, CDCl3): δ 2.06 (s, 3 H, SCH3), 2.08 (s, 
3 H, COCH3), 2.17 (pent, 2 H, CH2CH2CH2), 2.70 (t, J = 7.2 Hz, 2 H, SCH2), 2.89-2.95 
(m, 4 H, ArCH2, CH2CH), 3.32 (t, J = 6.2 Hz, 2 H, NCH2), 3.96 (t, J = 7.1 Hz, 2 H, OCH2), 
4.70 (m, 1H, CH2CH), 6.94 (m, 2 H, aromatic H), 7.20 (m, 2 H, aromatic H), 7.58 (d, J = 
8.2 Hz, 1 H, aromatic H), 7.64 (d, J = 8.2 Hz, 1 H, aromatic H), 7.90 (m, 1 H, aromatic H), 
7.99 (d, J = 2.6 Hz, 1 H, aromatic H), 8.74-8.79 (m, 2 H, aromatic H), 89.24 (d, J = 2.1 Hz, 
1 H, aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 15.69 (SCH3), 23.17 (COCH3, Ar-
CH2), 29.67 (CH2CH2CH2), 34.04 (SCH2), 36.31 (CH2CH), 37.57 (NCH2), 54.79 
(CH2CH), 72.98 (OCH2) 105.72, 115.42, 115.59, 120.98, 123.63, 129.63, 130.76, 130.89, 
132.24, 133.17, 135.00, 137.63, 147.89, 148.45, 149.31, 151.73, 162.88 (all Carom), 170.08 
(C=O), 170.92 (C=O). Anal. Calcd. C31H32Cl2FN5O3S (644.59): C 57.76, H 5.00, N 10.86; 
Found C 57.70, H 5.06, N 10.80. 






Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 36 
gave the title compound 9 as a white crystalline solid (yield 60%). M. p. 126-127 oC. -
[α]D
20= –18.0 (c = 0.00455, EtOH). IR (neat): 3663, 3282, 3066, 2921, 1664, 1593, 1511, 
1482, 1319, 1223, 1150 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.92 (pent, 2 H, 
CH2CH2CH2), 2.08 (s, 3 H, SCH3), 2.54 (s, 3H, SO2CH3), 2.64 (t, J = 7.3 Hz, 2 H, SCH2), 
2.89-2.93 (m, 3 H, ArCH2, CH2CH), 3.20 (dd, J = 5.1, 12.2 Hz, 1 H, CH2CH), 3.44 (t, J = 
6.4 Hz, 2 H, NCH2), 3.96-3.99 (m, 3 H, OCH2, CH2CH), 4.93 (d, J = 5.6 Hz, 1 H, NH), 
6.42 (br. s, 1 H, NH), 7.03 (m, 2 H, aromatic H), 7.19 (m, 2 H, aromatic H), 7.38 (dd, J = 
2.7, 8.5 Hz, 1 H, aromatic H), 7.55 (d, J = 8.5 Hz, 1 H, aromatic H), 7.65 (dd, J = 2.4, 8.5 
Hz, 1 H, aromatic H), 7.93 (d, J = 2.4 Hz, 1 H, aromatic H), 8.00 (m, 1 H, aromatic H), 
8.63 (dd, J = 2.1, 7.6 Hz, 1 H, aromatic H), 8.90 (d, J = 2.1, 1 H, aromatic H). 13C NMR 
(125.7 MHz, CDCl3): δ 15.69 (SCH3), 23.22 (Ar-CH2), 29.57 (CH2CH2CH2), 34.03 
(SCH2), 36.56 (CH2CH), 37.97 (NCH2), 40.50 (SO2CH3), 58.94 (CH2CH), 72.97 (OCH2), 
105.78, 115.92, 116.08, 121.09, 123.58, 123.72, 129.63, 130.81, 130.93, 131.03, 133.17, 
134.94, 137.69, 148.56, 149.41 (all Carom), 170.34 (C=O). Anal. Calcd. C30H32Cl2FN5O4S2 
(680.64): C 52.94, H 4.74, N 10.29; Found C 52.88, H 4.80, N 10.21. 
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Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 42 
gave the title compound 10 as a colorless solid (yield 61%). M. p. 131-132 oC. – [α]D
20 = –
19.1 (c = 0.00335, EtOH). IR (neat): 3275, 3039, 2917, 1652, 1591, 1483, 1368, 1284, 
1030 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.82 (pent, 2H, CH2CH2CH2), 1.97 (s, 3 H, 
COCH3), 2.07 (s, 3 H, SCH3), 2.62 (t, J = 7.1 Hz, 2 H, SCH2), 2.84-2.93 (m, 3 H, ArCH2, 
CH2CH), 3.01 (dd, J = 5.5, 12.2 Hz, 1 H, CH2CH), 3.32 (m, 2 H, NCH2), 3.74 (s, 3 H, 
OCH3), 3.88 (t, J = 6.2 Hz, 2 H, OCH2), 4.49 (m, 1 H, CH2CH), 6.05 (br. s, 1 H, NH), 6.18 
(d, J = 6.7 Hz, 1 H, NH), 6.80 (d, J = 8.5 Hz, 2 H, aromatic H), 7.10 (d, J = 8.5 Hz, 2 H, 
aromatic H), 7.39 (m, 1 H, aromatic H), 7.54 (d, J = 8.8 Hz, 1 H, aromatic H), 7.65 (dd, J 
= 2.4, 8.8 Hz, 1 H, aromatic H), 7.91 (d, J = 2.4 Hz, 1 H, aromatic H), 8.00 (d, J = 7.9 Hz, 
1 H, aromatic H), 8.63 (d, J = 4.9 Hz, 1 H, aromatic H), 8.90 (s, 1 H, aromatic H). 13C 
NMR (125.7 MHz, CDCl3): δ 15.71 (SCH3), 23.12 (COCH3), 23.19 (Ar-CH2), 32.75 
(CH2CH2CH2), 34.07 (SCH2), 36.24 (CH2CH), 37.57 (NCH2), 54.97 (OCH3), 55.22 
(CH2CH), 73.05 (OCH2), 105.82, 114.07, 120.95, 123.63, 123.92, 128.48, 130.22, 130.90, 
133.20, 135.80, 137.58, 147.37, 147.46, 148.20, 151.83, 158.65 (all Carom), 170.00 (C=O), 
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171.17 (C=O). Anal. Calcd. C32H35Cl2N5O4S (656.62): C 58.53, H 5.37, N 10.67; Found 
C 58.47, H 5.43, N 10.60. 




Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 44 
gave the title compound 11 as a yellow thick gum (yield 64%). – [𝛼]D
20= –13.9 (c = 0.0049, 
EtOH). IR (neat): 3403, 3066, 2925, 2835, 1667, 1592, 1514, 1482, 1321, 1248, 1150 cm-
1. 1H NMR (500 MHz, CDCl3): δ 1.92 (pent, 2 H, CH2CH2CH2), 2.07 (s, 3 H, SCH3), 2.50 
(s, 3 H, SO2CH3), 2.64 (t, J = 7.3 Hz, 2 H, SCH2), 2.82-2.90 (m, 3 H, ArCH2, CH2CH), 
3.19 (dd, J = 6.4, 14.0 Hz, 1 H, CH2CH), 3.40 (m, 2 H, NCH2), 3.77 (s, 3 H, OCH3), 3.96 
(t, J = 6.4 Hz, 2 H, OCH2), 4.48 (m, 1 H, CH2CH), 5.04 (br. s, 1 H, NH), 6.22 (br. s, 1 H, 
NH), 6.86 (d, J = 8.5 Hz, 2 H, aromatic H), 7.14 (d, J = 8.5 Hz, 2 H, aromatic H), 7.38 (m, 
1 H, aromatic H), 7.55 (d, J = 8.8 Hz, 1 H, aromatic H), 7.66 (dd, J = 2.4, 8.8 Hz, 1 H, 
aromatic-H), 7.92 (d, J = 2.45 Hz, 1 H, aromatic H), 8.00 (d, J = 7.9 Hz, 1 H, aromatic H), 
8.63 (m, 1 H, aromatic H), 8.90 (d, J = 2.1 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, 
CDCl3): δ 15.67 (SCH3), 23.19 (Ar-CH2), 29.61 (CH2CH2CH2), 34.02 (SCH2), 36.48 
(CH2CH), 37.87 (NCH2), 40.19 (SO2CH3), 55.33 (OCH3), 59.18 (CH2CH), 73.02 (OCH2), 
107 
 
114.04, 114.48, 121.06, 123.58, 123.72, 128.10, 129.66, 130.44, 130.75, 130.91, 133.16, 
134.96, 137.69, 147.92, 148.54, 149.34, 151.77, 159.09 (all Carom), 170.65 (C=O). Anal. 
Calcd. C31H35Cl2N5O5S2 (692.68): C 53.75, H 5.09, N 10.11; Found C 53.70, H 5.15, N 
10.03. 





Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 43 
yielded compound 12 as a colorless crystalline solid (yield 55%). M. p. 123-124 oC. – [𝛼]D
20 
= –8.9 (c = 0.00335, EtOH). IR (neat): 3427, 3314, 3042, 2974, 2922, 1714, 1592, 1513, 
1366, 1247, 1166 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.39 (s, 9 H, OC(CH3)3, 1.84 (pent, 
2 H, CH2CH2CH2), 2.06 (s, 3 H, SCH3), 2.62 (t, J = 7.5 Hz, 2 H, SCH2), 2.86 (t, J = 8.8 
Hz, 2 H, ArCH2), 2.93-3.02 (m, 2 H, CH2CH), 3.34 (m, 2 H, NCH2), 3.75 (s, 3 H, OCH3), 
3.91 (t, J = 6.4 Hz, 2 H, OCH2), 4.42 (m, 1 H, CH2CH), 5.04 (br. s, 1 H, NH), 6.01 (br. s, 
1 H, NH), 6.80 (d, J = 8.5 Hz, 2H, aromatic H), 7.10 (d, J =8.5 Hz, 2 H, aromatic H), 7.39 
(m, 1 H, aromatic H), 7.55 (d, J = 8.5 Hz, 1 H, aromatic H), 7.65 (dd, J = 2.4, 8.5 Hz, 1 H, 
aromatic H), 7.91 (d, J = 2.4 Hz, aromatic H), 8.00 (dd, J = 2.1, 7.6 Hz, 1 H, aromatic H), 
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8.63 (d, J = 7.9 Hz, 1 H, aromatic H), 8.90 (d, J = 2.1, 7.6 Hz, 1 H, aromatic H). 13C NMR 
(125.7 MHz, CDCl3): δ 15.66 (SCH3), 23.12 (Ar-CH2), 28.26 (OC(CH3)3), 29.70 
(CH2CH2CH2), 34.00 (SCH2), 36.28 (CH2CH), 37.59 (NCH2), 55.20 (OCH3), 55.24 
(CH2CH), 73.12 (OCH2), 79. 92 (OC(CH3)3), 105.74, 114.06, 120.95, 123.58, 123.63, 
129.60, 130.29, 130.76, 130.88, 133.17, 134.92, 137.62, 147.91, 148.52, 149.37, 151.76 
(all Carom), 158.60 (C=O), 171.54 (C=O). Anal. Calcd. C35H41Cl2N5O5S (387.52): C 58.82, 
H 5.78, N 9.80; Found C 58.77, H 5.82, N 9.74. 




Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 37 
yielded compound 13 as a light brown gum (yield 58%). – [𝛼]D
20 = –17.5 (c = 0.00365, 
EtOH). IR (neat): 3442, 3060, 2923, 1653, 1592, 1482, 1369, 1133 cm-1. 1H NMR (500 
MHz, CDCl3): δ 1.85 (pent, 2 H, CH2CH2CH2), 1.96 (s, 3 H, COCH3), 2.07 (s, 3 H, SCH3), 
2.62 (t, J = 7.0 Hz, 2 H, SCH2), 2.87 (t, J = 7.3 Hz, 2 H, ArCH2), 3.01 (dd, J = 5.5, 12.7 
Hz, 1 H, CH2CH), 3.09 (dd, J = 7.3, 12.7 Hz, 1 H, CH2CH), 3.35 (m, 2 H, NCH2), 3.93 (t, 
J = 7.0 Hz, 2 H, OCH2), 4.61 (m, 1H, CH2CH), 6.45 (br. s, 1 H, NH), 6.76 (br. s, 1 H, NH), 
7.20 (m, 1 H, aromatic H), 7.38 (m, 1 H, aromatic H), 7.54 (d, J = 8.8 Hz, 1 H, aromatic 
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H), 7.60 (m, 1 H, aromatic H), 7.64 (dd, J = 2.4, 8.8 Hz, 1 H, aromatic H), 7.91 (d, J = 2.5 
Hz, 1 H, aromatic H), 8.00 (m, 1 H, aromatic H), 8.40 (d, J = 2.1 Hz, 1 H, aromatic H), 
8.45 (dd, J = 2.1, 8.0 Hz, 1 H, aromatic H), 8.63 (dd, J = 2.1, 8.0 Hz, 1 H, aromatic H), 
8.89 (d, J = 2.1 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 15.68 (SCH3), 
23.11 (COCH3), 23.18 (Ar-CH2), 29.70 (CH2CH2CH2), 34.04 (SCH2), 35.58 (CH2CH), 
36.35 (NCH2), 54.23 (CH2CH), 73.06 (OCH2), 105.72, 120.98, 123.48, 123.58, 129.59, 
130.88, 132.31, 133.15, 134.92, 136.80,  137.66, 147.92, 148.36, 148.52, 149.73, 150.44, 
151.75 (all Carom), 170.18 (C=O), 170.69 (C=O). C30H32Cl2N6O3S (627.58): calcd. C 57.41, 
H 5.14, N 13.39; found C 57.36, H 5.19, N 13.34. 




Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 38 
yielded compound 14 as a colorless gum (yield 65%). – [𝛼]D
20= –28.3 (c = 0.0036, EtOH). 
IR (neat): 3546, 3386, 3060, 2979, 1674, 1592, 1483, 1318, 1150 cm-1. 1H NMR (500 MHz, 
CDCl3): δ 1.93 (pent, 2 H, CH2CH2CH2), 2.08 (s, 3 H, SCH3), 2.59 (s, 3 H, SO2CH3), 2.64 
(t, J = 7.6 Hz, 2 H, SCH2), 2.88 (t, J = 6.7 Hz, 2 H, ArCH2), 2.97 (dd, J = 5.8, 14.0 Hz, 1 
H, CH2CH), 3.20 (dd, J= 6.1, 14.0 Hz, 1 H, CH2CH), 3.45 (m, 2 H, NCH2), 3.97 (t, J = 5.8 
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Hz, 2 H, OCH2), 4.05 (m, 1 H, CH2CH), 5.36 (d, J = 5.8 Hz, 1 H, NH), 6.60 (br. s, 1 H, 
NH), 7.29 (dd, J = 4.9, 7.9 Hz, 1 H, aromatic H),  7.38 (dd, J = 4.9, 7.8 Hz, 1 H, aromatic 
H), 7.55 (d, J = 7.9 Hz, 1 H, aromatic H), 7.61 (m, 1 H, aromatic H), 7.65 (dd, J = 2.4, 8.8 
Hz, 1 H, aromatic H), 7.92 (d, J = 2.4 Hz, 1 H aromatic H), 8.00 (m, 1 H, aromatic H), 8.49 
(d, J = 2.1 Hz, 1 H, aromatic H), 8.52 (dd, J = 2.1, 8.1 Hz, 1 H, aromatic H), 8.63 (dd, J = 
2.1, 8.0 Hz, 1 H, aromatic H), 8.90 (d, J = 2.1 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, 
CDCl3): δ 15.69 (SCH3), 23.20 (Ar-CH2), 29.54 (CH2CH2CH2), 34.02 (SCH2), 36.06 
(CH2CH), 36.62 (NCH2), 40.95 (SO2CH3), 58.45 (CH2CH), 72.96 (OCH2), 121.07, 123.60, 
123.68, 123.75, 129.61, 130.78, 130.92, 132.15, 133.15, 134.94, 137.19, 137.66, 148.49, 
148.77, 149.37, 150.57, 151.71 (all Carom), 170.21 (C=O). Anal. Calcd. C29H32Cl2N6O4S2 
(663.64): C 52.48, H 4.86, N 12.66; Found C 52.42, H 4.90, N 12.60. 




Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 39 
yielded compound 15 as a light brown gum (yield 59%). – [𝛼]D
20 = –14.6 (c = 0.00315, 
EtOH). IR (neat): 3478, 3289, 3060, 2919, 1659, 1592, 1482, 1367, 1133 cm-1. 1H NMR 
(500 MHz, CDCl3): δ 1.85 (pent, 2 H, CH2CH2CH2), 1.96 (s, 3 H, COCH3), 2.08 (s, 3 H, 
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SCH3), 2.63 (t, J = 7.0 Hz, 2 H, SCH2), 2.86 (t, J = 7.3 Hz, 2H, ArCH2), 3.02 (dd, J = 6.4, 
12.7 Hz, 1 H, CH2CH), 3.06 (dd, J = 5.3, 12.7 Hz, 1 H, CH2CH), 3.36 (m, 2 H, NCH2), 
3.90 (t, J = 7.0 Hz, 2 H, OCH2), 4.60 (m, 1 H, CH2CH), 6.06 (br. s, 1 H, NH), 6.15 (br. s, 
1 H, NH), 7.14 (d, J = 6.1 Hz, 1 H, aromatic H), 7.39 (d, J = 6.6 Hz, 2 H, aromatic H), 7.54 
(d, J = 8.8 Hz, 1 H, aromatic H), 7.64 (dd, J = 2.4, 8.8 Hz, 1 H, aromatic H), 7.92 (d, J = 
2.4 Hz, 1 H, aromatic H), 8.00 (m, 1 H, aromatic H), 8.51 (d, J = 6.6 Hz, 2 H, aromatic H), 
8.62 (m, 1 H, aromatic H), 8.89 (d, J = 2.1 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, 
CDCl3): δ 15.69 (SCH3), 23.14 (COCH3), 23.20 (Ar-CH2), 29.54 (CH2CH2CH2), 34.02 
(SCH2), 36.40 (CH2CH), 37.38 (NCH2), 53.82 (CH2CH), 72.96 (OCH2), 121.07, 123.60, 
123.68, 123.75, 129.61, 130.78, 130.92, 132.15, 133.15, 134.94, 137.19, 137.66, 148.49, 
148.77, 149.37, 150.57, 151.71 (all Carom), 170.21 (C=O), 170.71 (C=O). Anal. Calcd. 
C30H32Cl2N6O3S (627.58): C 57.41, H 5.14, N 13.39; Found C 57.35, H 5.19, N 13.32. 




Following the same procedure adopted for the synthesis of 2, the reaction of 58 with 40 
yielded compound 16 as a colorless crystalline solid (yield 62%). M. p. 136-137 oC. – [𝛼]D
20 
= –20.0 (c = 0.0028, EtOH). IR (neat): 3373, 3281, 3062, 2919, 1675, 1592, 1482, 1415, 
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1319, 1183, 1150 cm-1. 1H NMR (500 MHz, CDCl3): δ 1.92 (pent, 2 H, CH2CH2CH2), 2.08 
(s, 3 H, SCH3), 2.59 (s, 3 H, SO2CH3), 2.65 (t, J = 7.7 Hz, 2 H, SCH2), 2.88 (t, J = 6.7 Hz, 
2 H, ArCH2), 2.97 (dd, J = 5.2, 13.7 Hz, 1 H, CH2CH), 3.20 (dd, J = 6.2, 13.7 Hz, 1 H, 
CH2CH), 3.47 (m, 2 H, NCH2), 3.97 (t, J = 5.9 Hz, 2 H, OCH2), 4.08 (m, 1 H, CH2CH), 
5.11 (m, 1 H, NH), 6.44 (br. s, 1 H, NH), 7.19 (d, J = 5.8 Hz, 1 H, aromatic H), 7.38 (d, J 
= 6.8 Hz, 2 H, aromatic H), 7.56 (d, J = 8.2 Hz, 1 H, aromatic H), 7.64 (dd, J = 2.4, 8.2 Hz, 
1 H, aromatic H), 7.92 (d, J = 2.4 Hz, 1 H, aromatic H), 8.00 (m, 1 H, aromatic H), 8.56 
(d, J = 6.8 Hz, 2 H, aromatic H), 8.62 (m, 1 H, aromatic H), 8.90 (d, J = 1.5 Hz, 1 H, 
aromatic H). 13C NMR (125.7 MHz, CDCl3): δ 15.71 (SCH3), 23.23 (Ar-CH2), 29.71 
(CH2CH2CH2), 34.02 (SCH2), 36.65 (CH2CH), 38.16 (NCH2), 40.95 (SO2CH3), 58.02 
(CH2CH), 72.91 (OCH2), 105.77, 121.10, 123.60, 123.70, 124.68, 130.94, 133.17, 134.92, 
137.66, 145.44, 148.52, 149.42, 150.35, 151.68 (all Carom), 169.98 (C=O). Anal. Calcd. 




4.4 GGTase-I and FTase assays 
Assays were carried out on black bottom 96-well plates and read on Tecon Micro Plate 
reader. The assay system (100 μl) containing 50 mM Tris-HCl (pH 7.4), 10 μM GGPP (in 
case of GGTase-I inhibition) or 10 μM FPP (in case of FTase inhibition), 5 μM dansyl-
GCVLL, 5 mM DTT, 5 mM MgCl2, 10 mM KCl, 50 μM ZnCl2, 0.04% n-Dodecyl β-D-
maltoside and indicated concentration of compounds dissolved in 1 μl DMSO. All the 
mixtures were incubated at 30 °C for 5 minutes for use. The reaction was initiated by the 
addition of 500 ng of pure GGTase-I or FTase and the fluorescence was measured for 20 
min (with readings taken every 1 min) at 30°C with the excitation wavelength at 340 nm 
and the emission wavelength at 520 nm. Each measurement was performed as triplicate 
and the IC50 values (concentrations resulting in 50% inhibition) were calculated from initial 
velocity of three independent measurements of five to seven different concentrations. 
GGTI-DU40 (Duke University) and FTI-277 (Sigma-Aldrich) were used as positive 
controls for GGTase-I and FTase inhibition, respectively. 
4.5 Western blot analysis 
MDAMB231 breast cancer cells were seeded at 6 × 104 cells/ well of a 6-well plate 24 
hours before drug treatment and incubated at 37°C in 5% CO2. The total volume in each 
well was maintained to 2 ml. The inhibitor compounds dissolved in DMSO were added in 
5 μM final concentration in each well whereas in the control well was added same volume 
of DMSO (10 L of DMSO (0.5%)). After 48 hours, cells were washed twice with cold 
PBS and lysed using cell extraction buffer 20 mM HEPES, pH 8.0, 1 mM EDTA, 3 mM 
dithiothreitol, 10 mM MgSO4, 150 mM NaCl, 1% Triton X-100. The protein concentration 
was quantified using the Pierce BCA Protein Assay kit (Thermo Scientific). Protein 
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samples (20–30 μg) were separated by 10% SDS-PAGE, transferred onto an Immun-Blot 
PVDF membrane (Bio-rad) and blotted with Rap1A antibody (Santa Cruz Biotechnology, 
Inc. CA). GGTI- DU40 was used as the positive control inhibitor, tubulin (Sigma) was 
used as the loading control for the immunoblot and visualized by Western Lightning-ECL 
(Millipore). 
4.6 Cell proliferation assay 
MDA-MB-231 breast cancer cells were cultured in 96-well microplates (5000 cells per 
well) for 24 h and then treated with compounds at different concentrations ranging from 2 
μM -32 μM for 48 h. The cytotoxicity of compounds in MDA-MB-231 cells was evaluated 
based on its effect on cell growth which was determined by using CellTiter 96® Aqueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI) at 48 hours. Briefly, 10 μl 
of CellTiter 96 Aqueous One Solution Reagent was added into each well and incubated for 
1 h at 37°C in a humidified 5% CO2 incubator. The absorbance measurement was done at 
490nm (Tecon Micro plate reader) and plotted in the graph using Prism. Each experiment 
was performed in triplicate and repeated three times. The cytotoxic effects of the extracts 
were estimated in terms of growth inhibition percentage and expressed as IC50 which is the 
concentration of compound which reduces the absorbance of treated cells by 50% with 
reference to the control (DMSO treated cells). 
4.7 Computational methods 
The crystal structure of the GGTase-I complexed with a GGPP Analog and a 
KKKSKTKCVIL peptide (PDB ID: 1N4Q) was employed in the docking calculations 
performed with Glide 6.2 (Schrodinger, LLC). Hydrogen atoms were added to the crystal 
structure, and the complex was submitted to a series of restrained, partial minimizations 
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using the OPLS-AA force field within the “Protein and Ligand Preparation” module of 
Glide. Two docking runs were performed, the first keeping the peptide KKKSKTKCVIL 
and the second by removing the peptide prior to the docking calculation. To compensate 
for the fixed protein structure, which is not expected to be optimal for a particular ligand, 
the van der Waals radii for nonpolar ligand atoms were scaled by a factor of 0.8, thereby 
decreasing penalties for close contacts. Receptor atoms were not scaled. For the protein 
preparation, grid generation, and ligand docking procedures, the default Glide settings were 
used. The compound 2 was preprocessed with the Glide module “LigPrep”, which ensured 
proper protonation and tautomerization states. The compounds was docked and scored 
using the Glide standard precision (SP) mode and subsequently the extra precision (XP) 
mode. In essence, Glide performs a thorough conformational search for a ligand; then it 
determines all reasonable orientations (“poses”) for each low-energy conformer in the 
designated binding site. In the process, torsional degrees of the ligand are relaxed, though 
the protein conformation is fixed. The SP “scoring function” is applied to judge the poses 
by considering, for example, hydrophobic and electrostatic interactions, hydrogen bonding, 
steric clashes, desolvation and internal energy of the ligand, and possible trapped or 
bridging water molecules in the binding site. In XP mode, the poses are further relaxed by 
complete energy minimizations. The resultant more accurate structures provide a basis for 
more detailed evaluation of contributions from explicit water molecules in the binding site 




In conclusion, we synthesized a series of pyrazole based GGTase-I inhibitors which are 
structural analogues of GGT1-DU40, a potent GGTase-I inhibitor. All synthesized 
compounds were evaluated for their in vitro inhibition against GGTase-I and FTase 
enzyme which revealed a clear trend of decreased inhibitory activity for propanamides (6-
16) compared to butanamides (2-5). Among the tested compounds, 2 (IC50 = 2.4 µM) 
exhibited the highest activity and turned out to be more active than the control compound 
1 (DU40). In addition, the activity of 2 was slightly diminished, but yet comparable to 1, 
when the fluoro moiety in 2 was replaced with a methoxy group to produce 5 (IC50 = 3.1 
µM). The screening results of in vitro inhibition against FTase enzyme revealed that all the 
target compounds were inactive at 100 µM concentration which suggested that they are 
selective inhibitors of GGTase-I. The efficiency of the target compounds was further 
validated by western blot analysis in MDA-MB-231 cell line, which highlighted the very 
high inhibitory cellular activity of 2 and 5  compared to the control compound GGTI-DU40 
(IC50 = 3.3 µM). The target compounds were also tested for the anti-proliferative efficacies 
against the MDA-MB-231 cell line which revealed significantly higher activity of 2 (IC50 
= 7.6 µM) compared to 1 (IC50 = 23.0 µM). Molecular docking studies of 2 with the crystal 
structure of GGTase-I complexed with a GGPP Analog and a KKKSKTKCVIL peptide 
revealed several hydrogen-bonding interactions and π-π contacts between 2 and the binding 
pocket of GGTase-I. The optimized scaffold of 2, showing increased potency merits its 
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